<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id>
<journal-title>Frontiers in Bioengineering and Biotechnology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Bioeng. Biotechnol.</abbrev-journal-title>
<issn pub-type="epub">2296-4185</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1504785</article-id>
<article-id pub-id-type="doi">10.3389/fbioe.2025.1504785</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Bioengineering and Biotechnology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Cofactor engineering for improved production of 2,4-dihydroxybutyric acid via the synthetic homoserine pathway</article-title>
<alt-title alt-title-type="left-running-head">Ihle et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fbioe.2025.1504785">10.3389/fbioe.2025.1504785</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ihle</surname>
<given-names>Nadine</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2854746/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gr&#xfc;&#xdf;ner</surname>
<given-names>Laura</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alkim</surname>
<given-names>Ceren</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2021358/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nguyen</surname>
<given-names>T. A. Stefanie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2973032/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walther</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2146245/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fraz&#xe3;o</surname>
<given-names>Cl&#xe1;udio J. R.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2858310/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Chair of Bioprocess Engineering</institution>, <institution>Institute of Natural Materials Technology</institution>, <institution>TU Dresden</institution>, <addr-line>Dresden</addr-line>, <country>Germany</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Toulouse Biotechnology Institute</institution>, <institution>UMR INSA-CNRS5504 and UMR INSA-INRAE 792</institution>, <addr-line>Toulouse</addr-line>, <country>France</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/242262/overview">Ruud Weusthuis</ext-link>, Wageningen University and Research, Netherlands</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/827366/overview">Zhiming Rao</ext-link>, Jiangnan University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/46328/overview">Roland Wohlgemuth</ext-link>, Lodz University of Technology, Poland</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Cl&#xe1;udio J. R. Fraz&#xe3;o, <email>claudio.frazao@tu-dresden.de</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>02</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>13</volume>
<elocation-id>1504785</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>10</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>01</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Ihle, Gr&#xfc;&#xdf;ner, Alkim, Nguyen, Walther and Fraz&#xe3;o.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Ihle, Gr&#xfc;&#xdf;ner, Alkim, Nguyen, Walther and Fraz&#xe3;o</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>(L)-2,4-dihydroxybutyrate (DHB) is a versatile compound that can serve as a precursor for the synthesis of the methionine analog 2-hydroxy-4-(methylthio)butyrate and new advanced polymers. We previously implemented in <italic>Escherichia coli</italic> an artificial biosynthetic pathway for the aerobic production of DHB from glucose, which relies on the deamination of (L)-homoserine followed by the reduction of 2-oxo-4-hydroxybutyrate (OHB) and yields DHB by an enzyme-bearing NADH-dependent OHB reductase activity. Under aerobic conditions, using NADPH as a cofactor is more favorable for reduction processes. We report the construction of an NADPH-dependent OHB reductase and increased intracellular NADPH supply by metabolic engineering to improve DHB production. Key cofactor discriminating positions were identified in the previously engineered NADH-dependent OHB reductase (<italic>E. coli</italic> malate dehydrogenase I12V:R81A:M85Q:D86S:G179D) and tested by mutational scanning. The two point mutations D34G:I35R were found to increase the specificity for NADPH by more than three orders of magnitude. Using the new OHB reductase enzyme, replacing the homoserine transaminase with the improved variant Ec.AlaC A142P:Y275D and increasing the NADPH supply by overexpressing the <italic>pntAB</italic> gene encoding the membrane-bound transhydrogenase yielded a strain that produced DHB from glucose at a yield of 0.25 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup> in shake-flask experiments, which corresponds to a 50% increase compared to previous producer strains. Upon 24&#xa0;h of batch cultivation of the most advanced DHB producer strain constructed in this work, a volumetric productivity of 0.83 mmol<sub>DHB</sub> L<sup>&#x2212;1</sup>&#xa0;h<sup>&#x2212;1</sup> was reached.</p>
</abstract>
<kwd-group>
<kwd>enzyme engineering</kwd>
<kwd>strain engineering</kwd>
<kwd>cofactor specificity</kwd>
<kwd>synthetic metabolic pathway</kwd>
<kwd>2,4-dihydroxybutyric acid</kwd>
<kwd>homoserine</kwd>
<kwd>
<italic>Escherichia coli</italic>
</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Synthetic Biology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>(L)-2,4-dihydroxybutyrate (DHB) is a versatile compound of growing industrial relevance, as it can serve as a precursor for the chemical production of the methionine analog 2-hydroxy-4-(methylthio)butyrate (HMTB) used in animal nutrition (<xref ref-type="bibr" rid="B45">Walther et al., 2017a</xref>) or as a building block for new advanced biopolymers (<xref ref-type="bibr" rid="B19">Fran&#xe7;ois, 2023</xref>). Furthermore, DHB can serve as a precursor for the synthesis of 1,3-propanediol (<xref ref-type="bibr" rid="B22">Fraz&#xe3;o et al., 2019</xref>) or 1,2,4-butanetriol (<xref ref-type="bibr" rid="B31">Li et al., 2014</xref>). Although the occurrence of DHB at trace levels in patients with succinic semialdehyde dehydrogenase deficiency has been described previously (<xref ref-type="bibr" rid="B43">Shinka et al., 2002</xref>), there is no annotated natural metabolic pathway for its biosynthesis.</p>
<p>Aided by synthetic biology and enzyme engineering, we and others have previously reported three artificial biosynthetic pathways for the aerobic, microbial production of DHB starting from the widely abundant and inexpensive sugar glucose (<xref ref-type="bibr" rid="B47">Walther et al., 2017b</xref>; <xref ref-type="bibr" rid="B46">Walther et al., 2015</xref>; <xref ref-type="bibr" rid="B45">Walther et al., 2017a</xref>). It is of note, however, that all the new routes are fully compatible with the use of other sugars (e.g., xylose, mannose, sucrose) or alcohols (e.g., methanol, ethylene glycol) as starting carbon sources, as all DHB pathways start from naturally occurring metabolites (homoserine, malate, or glyoxylate/acetyl-CoA). The different metabolic routes were tested in <italic>Escherichia coli.</italic> The highest reported titers (7.9 &#xb1; 0.01&#xa0;mM) and yields (0.10 &#xb1; 0.01 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup>) in shake-flask cultivations with glucose as carbon source have been achieved with the DHB pathway proceeding through the characteristic natural intermediate (L)-homoserine (<xref ref-type="bibr" rid="B21">Fraz&#xe3;o et al., 2018</xref>). This route enables DHB synthesis via sequential deamination of (L)-homoserine by homoserine transaminase activity and reduction of 2-oxo-4-hydroxybutyrate (OHB) by an OHB reductase activity (<xref ref-type="fig" rid="F1">Figure 1</xref>). In a previous study, we reported the construction of the highly active NADH-dependent OHB reductase Ec.Mdh<sup>5Q</sup> (<xref ref-type="bibr" rid="B21">Fraz&#xe3;o et al., 2018</xref>). The mutant variant descends from the parent NAD<sup>&#x2b;</sup>-dependent (L)-malate dehydrogenase from <italic>E. coli</italic> (Ec.Mdh) and incorporates five mutations (I12V:R81A:M85Q:D86S:G179D) to yield the desired synthetic activity. However, the typical intracellular ratios of [NADH]/[NAD<sup>&#x2b;</sup>] and [NADPH]/[NADP<sup>&#x2b;</sup>] in <italic>E. coli</italic> cells cultivated under aerobic conditions are 0.03 and 60, respectively (<xref ref-type="bibr" rid="B2">Bennett et al., 2009</xref>), which suggests that the utilization of NADPH as a cofactor in aerobic reduction processes may be more favorable. Therefore, employing an enzyme bearing NADPH-dependent OHB reductase activity could provide a strong advantage in terms of pathway performance.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Aerobic synthesis of (L)-2,4-dihydroxybutyric acid (DHB) from glucose via the artificial homoserine pathway (bluish-green) and applied strategies for increased NADPH availability in <italic>Escherichia coli</italic>. Abbreviations: 1,3bPG, 1,3-bisphospho-glycerate; AcCoA, acetyl-CoA; ASP, aspartate; ASP-P, aspartyl phosphate; ASP-SA, aspartate semialdehyde; CIT, citrate; DHAP, dihydroxyacetone phosphate; F1,6bP, fructose-1,6-bisphosphate; F6P, fructose-6-phosphate; FUM, fumarate; G3P, glyceraldehyde-3-phosphate; G6P, glucose-6-phosphate; Glc, glucose; ICI, isocitrate; (L)-DHB, (L)-2,4-dihydroxybutyrate; (L)-HS, (L)-homoserine; (L)-MET, (L)-methionine; (L)-THR, (L)-threonine; MAL, malate; OAA, oxaloacetate; OHB, 2-oxo-4-hydroxybutyrate; O-P-(L)-HS, <italic>O</italic>-phospho-L-homoserine; O-Suc-(L)-HS, <italic>O</italic>-succinyl-(L)-homoserine; PEP, phosphoenolpyruvate; PP pathway, pentose phosphate pathway; PYR, pyruvate; SUC, succinate; SucCoA, succinyl-CoA; TCA, tricarboxylic acid cycle; &#x3b1;-KG, &#x3b1;-ketoglutarate; Gene names are written in italics. <italic>Ec.pfkA</italic>&#x2013;gene encoding 6-phosphofructokinase; <italic>Ec.sthA</italic>&#x2013;gene encoding soluble pyridine nucleotide transhydrogenase; <italic>Ec.pntAB</italic>&#x2013;gene encoding membrane-bound pyridine nucleotide transhydrogenase; <italic>Ec.ppc</italic>
<sub>
<italic>K620S</italic>
</sub>&#x2013;gene encoding aspartate/malate insensitive phosphoenolpyruvate carboxylase mutant (<xref ref-type="bibr" rid="B45">Walther et al., 2017a</xref>); <italic>Ec.thrA</italic>
<sub>
<italic>S345F</italic>
</sub>&#x2013;gene encoding threonine-insensitive bifunctional aspartate kinase/HMS dehydrogenase mutant (<xref ref-type="bibr" rid="B45">Walther et al., 2017a</xref>). The main glucose uptake pathway in <italic>Escherichia coli</italic> via the phosphoenolpyruvate-dependent glucose-specific phosphotransferase system (<xref ref-type="bibr" rid="B32">Liang et al., 2015</xref>) is marked by a bold arrow. Red crosses mark chromosomal gene deletion, and the red arrow indicates chromosomal overexpression. Bluish-green arrows mark the enzyme activities of synthetic homoserine-dependent pathways provided by plasmid-based expression.</p>
</caption>
<graphic xlink:href="fbioe-13-1504785-g001.tif"/>
</fig>
<p>In the absence of annotated naturally occurring enzymes with NADPH-dependent OHB reductase activity, we chose NADH-dependent Ec.Mdh<sup>5Q</sup> as the template enzyme to engineer the required activity. Previous studies have focused on engineering the nicotinamide cofactor specificity of oxidoreductases following rational approaches [as reviewed by <xref ref-type="bibr" rid="B8">Ch&#xe1;nique and Parra (2018)</xref>] and typically rely on introducing amino acid substitutions in the co-enzyme binding site. Following this logic, we used comparative sequence and structural analyses supported by the use of a structure-guided web tool (<xref ref-type="bibr" rid="B7">Cahn et al., 2017</xref>) to engineer NADPH-dependent OHB reductase activity. The best-performing mutant, assessed by <italic>in vitro</italic> analysis, was subsequently introduced into a strain that produced DHB via the synthetic homoserine pathway. To demonstrate the full potential of our engineered NADPH-dependent OHB reductase variant and to prevent NADPH becoming a limiting factor in product synthesis, we transferred the DHB pathway into NADPH-overproducing <italic>E. coli</italic> strains (<xref ref-type="fig" rid="F1">Figure 1</xref>) expressing the improved transaminase variant <italic>Ec.alaC</italic>
<sub>
<italic>A142P:Y275D</italic>
</sub> and showed a 50% increased DHB yield in shake-flask cultivations with glucose as the only carbon source for the most advanced strain.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 Reagents and chemicals</title>
<p>Unless stated otherwise, chemicals and solvents were purchased from Sigma-Aldrich (Darmstadt, Germany). Restriction enzymes and kits for plasmid DNA isolation, gel DNA extraction, and PCR clean-up were purchased from NEB (Frankfurt am Main, Germany) and used according to the manufacturer&#x2019;s instructions. Primers were purchased from Sigma-Aldrich. Sanger sequencing was carried out by Genewiz (Leipzig, Germany).</p>
</sec>
<sec id="s2-2">
<title>2.2 Strains and plasmids</title>
<p>All strains and plasmids used in this study are listed in <xref ref-type="table" rid="T1">Tables 1</xref>, <xref ref-type="table" rid="T2">2</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Plasmids used in this study.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Plasmid</th>
<th align="left">Relevant characteristic</th>
<th align="left">Reference/Origin</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">pKD4</td>
<td align="left">R6K &#x3b3; ori, FRT-flanked Kan<sup>R</sup>, and Amp<sup>R</sup>
</td>
<td align="left">
<xref ref-type="bibr" rid="B16">Datsenko and Wanner (2000)</xref>
</td>
</tr>
<tr>
<td align="left">pKD46</td>
<td align="left">pSC101 ori, araC-P<sub>araB</sub>, &#x3bb;-Red recombinase system (<italic>&#x3b3;, &#x3b2;, exo</italic>, &#x3bb; tL3 terminator), and Amp<sup>R</sup>
</td>
<td align="left">
<xref ref-type="bibr" rid="B16">Datsenko and Wanner (2000)</xref>
</td>
</tr>
<tr>
<td align="left">pCP20</td>
<td align="left">pSC101 ori, Amp<sup>R</sup>, Cm<sup>R</sup>, and Flp</td>
<td align="left">
<xref ref-type="bibr" rid="B10">Cherepanov and Wilfried (1995)</xref>
</td>
</tr>
<tr>
<td colspan="3" align="left">
<italic>In vitro</italic> studies</td>
</tr>
<tr>
<td align="left">pET28a(&#x2b;)</td>
<td align="left">
<italic>f1</italic> origin, Kan<sup>R</sup>, and T7 promoter</td>
<td align="left">Novagen&#x2122;</td>
</tr>
<tr>
<td align="left">pET28-<italic>Ec-Mdh</italic>
<sup>
<italic>5Q</italic>
</sup>
</td>
<td align="left">pET28a(&#x2b;) derivative N-terminal His-tagged <italic>Ec.mdh</italic>
<sub>
<italic>R81A:M85Q:I12V:G179D:D86S</italic>
</sub>
</td>
<td align="left">
<xref ref-type="bibr" rid="B21">Fraz&#xe3;o et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">pET28-<italic>Ec-Mdh</italic>
<sup>
<italic>5Q</italic>
</sup>
<italic>-D34G</italic>
</td>
<td align="left">pET28a(&#x2b;) derivative with N-terminal His-tagged <italic>Ec.mdh</italic>
<sub>
<italic>R81A:M85Q:I12V:G179D:D86S:D34G</italic>
</sub>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">pET28-<italic>Ec-Mdh</italic>
<sup>
<italic>5Q</italic>
</sup>
<italic>-D34G:I35K</italic>
</td>
<td align="left">pET28a(&#x2b;) derivative with N-terminal His-tagged <italic>Ec.mdh</italic>
<sub>
<italic>R81A:M85Q:I12V:G179D:D86S:D34G:I35K</italic>
</sub>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">pET28-<italic>Ec-Mdh</italic>
<sup>
<italic>5Q</italic>
</sup>
<italic>-D34G:I35R</italic>
</td>
<td align="left">pET28a(&#x2b;) derivative with N-terminal His-tagged <italic>Ec.mdh</italic>
<sub>
<italic>R81A:M85Q:I12V:G179D:D86S:D34G:I35R</italic>
</sub>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">pET28-<italic>Ec-Mdh</italic>
<sup>
<italic>5Q</italic>
</sup>
<italic>-D34G:I35S</italic>
</td>
<td align="left">pET28a(&#x2b;) derivative with N-terminal His-tagged <italic>Ec.mdh</italic>
<sub>
<italic>R81A:M85Q:I12V:G179D:D86S:D34G:I35S</italic>
</sub>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">pET28-<italic>Ec-Mdh</italic>
<sup>
<italic>5Q</italic>
</sup>
<italic>-D34G:I35T</italic>
</td>
<td align="left">pET28a(&#x2b;) derivative with N-terminal His-tagged <italic>Ec.mdh</italic>
<sub>
<italic>R81A:M85Q:I12V:G179D:D86S:D34G:I35T</italic>
</sub>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td colspan="3" align="left">
<italic>In vivo</italic> DHB production</td>
</tr>
<tr>
<td align="left">pZA23</td>
<td align="left">
<italic>p15A</italic> origin, Kan<sup>R</sup>, and P<sub>A1lacO-1</sub> promoter</td>
<td align="left">Expressys</td>
</tr>
<tr>
<td align="left">pZA23-HS1-5Q</td>
<td align="left">pZA23 derivative carrying <italic>Ec.thrA</italic>
<sub>
<italic>S345F</italic>
</sub>, <italic>Ec.aspC</italic>, <italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup>, and <italic>Ec.ppc</italic>
<sub>
<italic>K620S</italic>
</sub>
</td>
<td align="left">
<xref ref-type="bibr" rid="B21">Fraz&#xe3;o et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">pZA23-HS1-7Q</td>
<td align="left">pZA23 derivative harboring <italic>Ec.thrA</italic>
<sub>
<italic>S345F</italic>
</sub>, <italic>Ec.aspC, Ec.mdh</italic>
<sup>
<italic>7Q</italic>
</sup>, and <italic>Ec.ppc</italic>
<sub>
<italic>K620S</italic>
</sub>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">pZA23-HS2-5Q</td>
<td align="left">pZA23 derivative harboring <italic>Ec.thrA</italic>
<sub>
<italic>S345F</italic>
</sub>, <italic>Ec.alaC</italic>
<sub>
<italic>A142P:Y275D</italic>
</sub>, <italic>Ec.Mdh</italic>
<sup>
<italic>5Q</italic>
</sup>, and <italic>Ec.ppc</italic>
<sub>
<italic>K620S</italic>
</sub>
</td>
<td align="left">
<xref ref-type="bibr" rid="B20">Frazao (2019)</xref>
</td>
</tr>
<tr>
<td align="left">pZA23-HS2-7Q</td>
<td align="left">pZA23 derivative harboring <italic>Ec.thrA</italic>
<sub>
<italic>S345F</italic>
</sub>, <italic>Ec.alaC</italic>
<sub>
<italic>A142P:Y275D</italic>
</sub>, <italic>Ec.mdh</italic>
<sup>
<italic>7Q</italic>
</sup>, and <italic>Ec.ppc</italic>
<sub>
<italic>K620S</italic>
</sub>
</td>
<td align="left">This study</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>
<italic>Escherichia coli</italic> strains used in this study.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Strain</th>
<th align="left">Genotype</th>
<th align="left">Reference/Origin</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">NEB<sup>&#xae;</sup> 5-alpha</td>
<td align="left">
<italic>E. coli fhuA2 &#x394;(argF-lacZ)U169 phoA glnV44 &#x3a6;80&#x394; (lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1</italic> hsdR17</td>
<td align="left">NEB&#x2122;</td>
</tr>
<tr>
<td align="left">BL21 (DE3)</td>
<td align="left">
<italic>E. coli fhuA2 [lon] ompT gal (&#x3bb; DE3) [dcm] &#x2206;hsdS</italic>
</td>
<td align="left">NEB&#x2122;</td>
</tr>
<tr>
<td align="left">MG1655</td>
<td align="left">
<italic>F</italic>
<sup>
<italic>&#x2212;</italic>
</sup> <italic>&#x3bb;</italic>
<sup>
<italic>-</italic>
</sup> <italic>ilvG- rfb-50 rph-1</italic>
</td>
<td align="left">ATCC</td>
</tr>
<tr>
<td align="left">bWL1221</td>
<td align="left">
<italic>E. coli</italic> MG1655 <italic>lldD</italic>
<sup>
<italic>proD-kan</italic>
</sup>
</td>
<td align="left">INSA Toulouse</td>
</tr>
<tr>
<td align="left">EcHS0</td>
<td align="left">
<italic>E. coli</italic> MG1655 <italic>&#x394;thrB &#x394;metA &#x394;ldhA</italic>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS1</td>
<td align="left">EcHS0 with pZA23-HS1-5Q (<italic>Ec.aspC</italic>, <italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup>
<italic>)</italic>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS2</td>
<td align="left">EcHS0 with pZA23-HS1-7Q (<italic>Ec.aspC</italic>, <italic>Ec.mdh</italic>
<sup>
<italic>7Q</italic>
</sup>
<italic>)</italic>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS3</td>
<td align="left">EcHS0 with pZA23-HS2-5Q (<italic>Ec.alaC</italic>
<sub>
<italic>A142P:Y275D</italic>
</sub>, <italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup>
<italic>)</italic>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS4</td>
<td align="left">EcHS0 with pZA23-HS2-7Q (<italic>Ec.alaC</italic>
<sub>
<italic>A142P:Y275D</italic>
</sub>, <italic>Ec.mdh</italic>
<sup>
<italic>7Q</italic>
</sup>
<italic>)</italic>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS5</td>
<td align="left">EcHS3 with <italic>&#x394;pfkA</italic>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS6</td>
<td align="left">EcHS3 with <italic>&#x394;sthA</italic>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS7</td>
<td align="left">EcHS3 with <italic>pntAB</italic>
<sup>
<italic>proD</italic>
</sup>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS8</td>
<td align="left">EcHS7 with <italic>&#x394;sthA</italic>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS9</td>
<td align="left">EcHS4 with <italic>&#x394;pfkA</italic>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS10</td>
<td align="left">EcHS4 with <italic>&#x394;sthA</italic>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS11</td>
<td align="left">EcHS4 with <italic>pntAB</italic>
<sup>
<italic>proD</italic>
</sup>
</td>
<td align="left">This study</td>
</tr>
<tr>
<td align="left">EcHS12</td>
<td align="left">EcHS11 with <italic>&#x394;sthA</italic>
</td>
<td align="left">This study</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-3">
<title>2.3 Media</title>
<p>For cloning procedures, protein production, and cell recovery from glycerol stocks (30% v/v) kept at &#x2212;80&#xb0;C, cells were cultivated in lysogeny broth (LB) medium (10&#xa0;g&#xa0;L<sup>&#x2212;1</sup> tryptone, 5&#xa0;g&#xa0;L<sup>&#x2212;1</sup> yeast extract and 10&#xa0;g&#xa0;L<sup>&#x2212;1</sup> NaCl). LB agar plates were prepared by adding 20&#xa0;g&#xa0;L<sup>&#x2212;1</sup> agar-agar to liquid LB.</p>
<p>For DHB production studies, cells were cultivated in M9 mineral medium (<xref ref-type="bibr" rid="B47">Walther et al., 2017b</xref>), containing 20&#xa0;g&#xa0;L<sup>&#x2212;1</sup> glucose, 100&#xa0;mM MOPS (pH adjusted to 7 with KOH), 18&#xa0;g&#xa0;L<sup>&#x2212;1</sup> Na<sub>2</sub>HPO<sub>4</sub>&#xb7;12H<sub>2</sub>O, 3&#xa0;g&#xa0;L<sup>&#x2212;1</sup> KH<sub>2</sub>PO<sub>4</sub>, 0.5&#xa0;g&#xa0;L<sup>&#x2212;1</sup> NaCl, 2&#xa0;g&#xa0;L<sup>&#x2212;1</sup> NH<sub>4</sub>Cl, 0.5&#xa0;g&#xa0;L<sup>&#x2212;1</sup> MgSO<sub>4</sub>&#xb7;7 H<sub>2</sub>O, 0.015&#xa0;g&#xa0;L<sup>&#x2212;1</sup> CaCl<sub>2</sub>&#xb7;2H<sub>2</sub>O, 0.010&#xa0;g&#xa0;L<sup>&#x2212;1</sup> FeCl<sub>3</sub>, 0.012&#xa0;g&#xa0;L<sup>&#x2212;1</sup> thiamine HCl, and trace elements (0.4&#xa0;mg&#xa0;L<sup>&#x2212;1</sup> Na<sub>2</sub>EDTA&#xb7;2H<sub>2</sub>O, 1.8&#xa0;mg&#xa0;L<sup>&#x2212;1</sup> CoCl<sub>2</sub>&#xb7;6H<sub>2</sub>O, 1.8&#xa0;mg&#xa0;L<sup>&#x2212;1</sup> ZnCl<sub>2</sub>SO<sub>4</sub>&#xb7;7H<sub>2</sub>O, 0.4&#xa0;mg&#xa0;L<sup>&#x2212;1</sup> Na<sub>2</sub>MoO<sub>4</sub>&#xb7;2H<sub>2</sub>O, 0.1&#xa0;mg&#xa0;L<sup>&#x2212;1</sup> H<sub>3</sub>BO<sub>3</sub>, 1.2&#xa0;mg&#xa0;L<sup>&#x2212;1</sup> MnSO<sub>4</sub>&#xb7;H<sub>2</sub>O, and 1.2&#xa0;mg&#xa0;L<sup>&#x2212;1</sup> CuCl<sub>2</sub>&#xb7;2H<sub>2</sub>O). (L)-methionine and (L)-threonine were added at a final concentration of 0.2&#xa0;g&#xa0;L<sup>&#x2212;1</sup> each to compensate for auxotrophies of the production strains. Where required, antibiotics were added at the following final concentrations: carbenicillin, 100&#xa0;mg&#xa0;L<sup>&#x2212;1</sup>, and kanamycin sulfate, 50&#xa0;mg&#xa0;L<sup>&#x2212;1</sup>.</p>
</sec>
<sec id="s2-4">
<title>2.4 Site-directed mutagenesis, gene expression, and protein purification for <italic>in vitro</italic> enzyme studies</title>
<p>Site-directed mutagenesis was performed via inverse PCR (<xref ref-type="bibr" rid="B50">Zheng et al., 2004</xref>) with primer pairs listed in <xref ref-type="sec" rid="s10">Supplementary Table S1</xref> using 6&#xa0;ng of vector pET28-<italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup> as a template (<xref ref-type="bibr" rid="B21">Fraz&#xe3;o et al., 2018</xref>). The PCR reaction was performed with Q5 polymerase (NEB). Compared to the manufacturer&#x2019;s instructions, the PCR cycle number was reduced to 19. After treatment with DpnI enzyme (NEB) to remove residual template DNA, plasmids were transformed into <italic>E. coli</italic> NEB<sup>&#xae;</sup> 5-alpha, and respective mutations were verified by DNA Sanger sequencing. The constructed plasmids are listed in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<p>N-terminally 6x-His-tagged enzymes were produced in <italic>E. coli</italic> BL21 (DE3) cells harboring respective pET28a expression vectors. A volume of 50&#xa0;mL of lysogeny broth (LB) medium supplemented with kanamycin in a 250&#xa0;mL unbaffled shake flask was inoculated at an initial optical density at 600&#xa0;nm (OD<sub>600</sub>) of 0.2 from an overnight LB culture. The culture was incubated at 37&#xb0;C and 220&#xa0;rpm. Heterologous protein expression was induced when OD<sub>600</sub> &#x3d; 0.6 by the addition of 1&#xa0;mM isopropyl &#x3b2;-D-1-thiogalactopyranoside (IPTG) to the medium. When an OD<sub>600</sub> of 2 was reached, cells were harvested by centrifugation (10&#xa0;min, 4,000 &#xd7;g, 4&#xb0;C), and the cell pellets were stored at &#x2212;20&#xb0;C until further analysis. To purify the His-tagged protein, frozen cell pellets were thawed on ice, resuspended in 50&#xa0;mM HEPES buffer containing 300&#xa0;mM NaCl (pH &#x3d; 7.5), and then disrupted using a sonicator (UDS 751, TOPAS, Germany, 4 &#xd7; 30&#xa0;s, 30% amplitude). Cell debris was removed from the soluble protein fraction by centrifugation (17,500 &#xd7;g, 15&#xa0;min, 4&#xb0;C). Upon washing of the Talon&#x2122; Cobalt affinity resin (Clontech, United States) according to the supplier&#x2019;s instructions, the crude extract was added to the resin and incubated in a tube rotator (VWR) at room temperature for 20&#xa0;min. After binding, a washing step with 50&#xa0;mM HEPES buffer containing 300&#xa0;mM NaCl (pH &#x3d; 7.5) and a subsequent washing step with the same buffer but additionally containing 15&#xa0;mM imidazole (pH &#x3d; 7.5) were carried out. Afterward, the protein bound to the resin was eluted with 200&#xa0;mM imidazole in 50&#xa0;mM HEPES buffer containing 300&#xa0;mM NaCl (pH &#x3d; 7.5) in a final volume of 500&#xa0;&#xb5;L. The concentration of purified protein was determined using the Bradford assay (Rotiquant<sup>&#xae;</sup>, Carl Roth), usually yielding a protein concentration of 3&#x2013;4&#xa0;mg&#xa0;mL<sup>&#x2212;1</sup> after purification.</p>
</sec>
<sec id="s2-5">
<title>2.5 OHB synthesis</title>
<p>OHB was prepared enzymatically starting from (L)-homoserine in a reaction catalyzed by the (L)-amino acid oxidase from <italic>Crotalus adamanteus</italic> (Sigma-Aldrich, A9253) as described by <xref ref-type="bibr" rid="B48">Wellner and Lichtenberg (1971)</xref>. The reaction mix contained 125&#xa0;mM (L)-homoserine, 100&#xa0;mM Tris-HCl (pH &#x3d; 7.8), and 4,374&#xa0;U&#xa0;mL<sup>&#x2212;1</sup> catalase from <italic>Aspergillus niger</italic> (Sigma-Aldrich, C3515), and 4.7&#xa0;U&#xa0;mL<sup>&#x2212;1</sup> (L)-amino acid oxidase. Control reactions were performed with the same reaction mix but in the absence of (L)-homoserine or (L)-amino acid oxidase, respectively. The reaction was performed for 4.5&#xa0;h at 37&#xb0;C and 220&#xa0;rpm. After incubation on ice for 1&#xa0;h, enzymes were removed using Amicon<sup>&#xae;</sup> Ultra Centrifugal filters (cut-off, &#x3c;10&#xa0;kDa; Merck, Germany) for 45&#xa0;min at 4&#xb0;C. Quantification of OHB was performed based on a ketone calibration curve (0&#x2013;300&#xa0;mM pyruvate). A volume of 100&#xa0;&#xb5;L of standard/sample was mixed with 1&#xa0;mL of a solution containing 1&#xa0;M sodium arsenate and 1&#xa0;M boric acid (pH &#x3d; 6.5). After incubation at room temperature for 30&#xa0;min, the absorbance at 325&#xa0;nm was measured. The absence of homoserine was further confirmed by high-performance liquid chromatography (HPLC) analysis.</p>
</sec>
<sec id="s2-6">
<title>2.6 OHB reductase assay</title>
<p>Enzymatic assays with purified enzyme were conducted at 37&#xb0;C in 96-well flat-bottomed microtiter plates with a final reaction volume of 250&#xa0;&#xb5;L per well. The reaction kinetics were monitored in a microplate reader (NanoQuant Plate&#x2122;, Infinite M200 PRO, TECAN) by following the characteristic absorption of NAD(P)H at 340&#xa0;nm. The reaction mixture contained 0.25&#xa0;mM NAD(P)H, 60&#xa0;mM Hepes (pH 7.0, adjusted with 5&#xa0;M KOH), 5&#xa0;mM MgCl<sub>2</sub>, 50&#xa0;mM KCl, and appropriate amounts of the purified enzyme. Reactions were started by adding 2&#xa0;mM OHB to assess the cofactor preference of the constructed enzyme variants. To determine the kinetic constants on the substrate of Ec.Mdh<sup>5Q</sup> and top-performing NADPH-dependent OHB reductase, specific activities were determined at variable OHB concentrations (0.005&#x2013;10&#xa0;mM) and 0.25&#xa0;mM of the preferred co-substrate. In order to estimate the kinetic constants on the cofactors, specific activities were determined at fixed amounts of substrate (OHB, 2&#xa0;mM) and variable amounts of NAD(P)H (0.03&#x2013;1&#xa0;mM). Experimental data were fitted to the Michaelis&#x2013;Menten model or to the substrate inhibition model using non-linear regression (Curve fitting tool, MATLAB R2021a). One unit (U) is defined as the amount of enzyme that catalyzes the conversion of 1&#xa0;&#xb5;mol of NAD(P)H per minute at pH 7.0 and 37&#xb0;C. K<sub>m,app</sub> [mM] is defined as the apparent Michaelis&#x2013;Menten constant, K<sub>i</sub> [mM] is the substrate inhibition constant, v<sub>max,app</sub> [U mg<sup>&#x2212;1</sup>] is the apparent maximum reaction speed, and k<sub>cat,app</sub> is the apparent catalytic constant [s<sup>&#x2212;1</sup>]. The catalytic efficiency is described by k<sub>cat</sub>/K<sub>m</sub> [mM s<sup>&#x2212;1</sup>] (<xref ref-type="bibr" rid="B12">Chmiel, 2018</xref>). The specificity for NADPH is described as (k<sub>cat,app</sub>/K<sub>m,app</sub>)<sub>NADPH</sub>/(k<sub>cat,app</sub>/K<sub>m,app</sub>)<sub>NADH</sub>, calculated from the mean values of k<sub>cat</sub> and K<sub>m</sub> (<xref ref-type="bibr" rid="B7">Cahn et al., 2017</xref>). We furthermore define the overall catalytic efficiency with respect to substrate conversion in the presence of the preferred cofactor as (k<sub>cat,app</sub>/K<sub>m,app</sub>)<sub>OHB</sub> &#xd7; (k<sub>cat,app</sub>/K<sub>m,app</sub>)<sub>NAD(P)H</sub>.</p>
</sec>
<sec id="s2-7">
<title>2.7 Plasmid construction for <italic>in vivo</italic> DHB biosynthesis</title>
<p>All plasmids constructed and used for <italic>in vivo</italic> DHB synthesis are listed in <xref ref-type="table" rid="T1">Table 1</xref>. The vectors are based on the pZA23 backbone of the pZ expression system (Expressys). Plasmids pZA23-HS1-5Q (<italic>Ec.aspC, Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup>) and pZA23-HS2-5Q (<italic>Ec.alaC</italic>
<sub>
<italic>A142P:Y275D</italic>
</sub>, <italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup>) were a kind gift of Prof. J. M. Fran&#xe7;ois from Toulouse Biotechnology Institute, INSA Toulouse, France, and served as the basis for gene replacements. To replace OHB reductase-encoding gene <italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup>, the gene <italic>Ec.mdh</italic>
<sup>
<italic>7Q</italic>
</sup> was first amplified by PCR from the corresponding pET28 vector using the primers TW2949 and TW2427 listed in <xref ref-type="sec" rid="s10">Supplementary Table S1</xref>, thereby introducing 5&#x2032; overhangs containing NotI and XbaI restriction sites. Backbone vectors pZA23-HS1-5Q and pZA23-HS2-5Q and insert were digested with the restriction enzymes NotI and XbaI (NEB). The digested backbone was further treated with Antarctic phosphatase (NEB). After DNA purification by gel extraction (Gel Extraction Kit, NEB), the backbone and insert were ligated using T4 DNA ligase (NEB) according to the provider&#x2019;s protocol. After verification via sequencing, plasmids were transformed into appropriate host strains.</p>
</sec>
<sec id="s2-8">
<title>2.8 Strain construction</title>
<p>All <italic>E. coli</italic> strains constructed and used are listed in <xref ref-type="table" rid="T2">Table 2</xref>. Chromosomal gene deletions in <italic>E. coli</italic> MG1655 were introduced by P1vir phage transduction (<xref ref-type="bibr" rid="B30">Lennox, 1955</xref>) using single-gene knockout mutants from the Keio collection (<xref ref-type="bibr" rid="B1">Baba et al., 2006</xref>) as donor strains. After transduction, the kanamycin resistance cassettes were removed using flippase (FLP) recombinase-catalyzed excision. The FLP recombinase was expressed from pCP20 (<xref ref-type="bibr" rid="B10">Cherepanov and Wilfried, 1995</xref>). Gene deletions and successful removal of resistance cassettes were confirmed by diagnostic PCR (Primers listed in <xref ref-type="sec" rid="s10">Supplementary Table S1</xref>) using DreamTaq polymerase (ThermoFisher Scientific), following the protocol provided by the manufacturer. Afterward, a new round of chromosomal modification was initiated, and the procedure was repeated until all target deletions were introduced.</p>
<p>For chromosomal overexpression of <italic>Ec.pntAB</italic>, the native chromosomal 5&#x2032;-untranslated region of the gene was replaced by the insulated constitutive promoter proD (<xref ref-type="bibr" rid="B17">Davis et al., 2011</xref>) via PCR-mediated &#x3bb;-Red recombination following the protocol of <xref ref-type="bibr" rid="B16">Datsenko and Wanner (2000)</xref>. The FRT-kan-FRT cassette fused to proD promoter sequence with 50&#xa0;bp 5&#x2032;-extensions homologous to the target genomic locus was amplified by PCR (primers are listed in <xref ref-type="sec" rid="s10">Supplementary Table S1</xref>) from the genomic DNA of strain bWL1221 in our lab collection (kindly provided by Prof. J. M. Fran&#xe7;ois from Toulouse Biotechnology Institute, INSA Toulouse, France). Recipient cells were transformed with the helper plasmid pKD46 (<xref ref-type="bibr" rid="B16">Datsenko and Wanner, 2000</xref>) for expression of &#x3bb;-Red recombination genes and with linearized, gel-purified PCR product. Successful integration was confirmed by colony PCR, as described above. After kan-cassette removal using FLP recombinase expressed from pCP20, the chromosomal promoter exchange was furthermore confirmed via DNA sequencing.</p>
</sec>
<sec id="s2-9">
<title>2.9 Shake-flask cultivation for DHB production</title>
<p>All cell cultivations were performed at 37&#xb0;C, 220&#xa0;rpm in an orbital shaker (Ecotron, Infors). First, pre-cultures were inoculated with a single colony picked from an LB agar plate and cultivated in 3&#xa0;mL LB media (15&#xa0;mL Falcon tube lying flat), and 50&#xa0;&#x3bc;g&#xa0;mL<sup>&#x2212;1</sup> kanamycin was added to the strains harboring pZA23 plasmids. After 8&#xa0;h, a volume of 0.5&#xa0;mL of the first pre-culture was transferred to 10&#xa0;mL of M9 mineral medium, supplemented with (L)-methionine (0.2&#xa0;g&#xa0;L<sup>&#x2212;1</sup>), (L)-threonine (0.2&#xa0;g&#xa0;L<sup>&#x2212;1</sup>), and kanamycin. After 16&#xa0;h of cultivation, cells were harvested by centrifugation in a table-top centrifuge (5&#xa0;min, 6,000 &#xd7;g, room temperature). The main cultures were carried out in 25&#xa0;mL M9 media supplemented with (L)-methionine (0.2&#xa0;g&#xa0;L<sup>&#x2212;1</sup>), (L)-threonine (0.2&#xa0;g&#xa0;L<sup>&#x2212;1</sup>), and kanamycin in 250&#xa0;mL baffled shake flasks. The main cultures were inoculated with the harvested cells at a starting OD<sub>600</sub> of 0.2. When an OD<sub>600</sub> of &#x223c;0.6 was reached, 1&#xa0;mM IPTG was added to induce the expression of pathway genes. Samples were regularly withdrawn and centrifuged (2&#xa0;min, 16,000 &#xd7;g, room temperature), and the supernatant was kept at &#x2212;20&#xb0;C until further analysis.</p>
</sec>
<sec id="s2-10">
<title>2.10 Analytical methods</title>
<p>Extracellular metabolites (glucose, DHB, acetate, and lactate) in supernatant samples from cultivations were analyzed using HPLC. The samples (1&#xa0;mL) were filter sterilized with 0.2&#xa0;&#xb5;m filters, transferred into 2&#xa0;mL HPLC sample vials, and subsequently analyzed with the Dionex UltiMate 3000 UHPLC system (Thermo Scientific). The device was equipped with an RI and UV/Vis detector. For separation, a Rezex&#x2122; ROA-Organic Acid H<sup>&#x2b;</sup> (8%) column (Phenomenex) with a size of 300&#xa0;mm &#xd7; 7.8&#xa0;mm was used, protected by a SecurityGuard&#x2122; Carbo H<sup>&#x2b;</sup> pre-column (4&#xa0;mm &#xd7; 3&#xa0;mm, Phenomenex). A sample volume of 20&#xa0;&#xb5;L was injected, and analytes were eluted using 0.5&#xa0;mM H<sub>2</sub>SO<sub>4</sub> as mobile phase, with a flow rate of 0.5&#xa0;mL&#xa0;min<sup>&#x2212;1</sup>. The column oven temperature was set to 80&#xb0;C, and the temperature of the autosampler was set to 6&#xb0;C.</p>
<p>Depending on the concentration range, the presence of DHB was verified by LC/MS analyses using our previously described method (<xref ref-type="bibr" rid="B23">Fraz&#xe3;o et al., 2023</xref>). The LC/MS platform consists of a Vanquish and a Thermo Scientific&#x2122; Q Exactive&#x2122; Focus (ThermoFisher Scientific), controlled by Xcalibur software (version 2.1, ThermoFisher Scientific). Separation by liquid chromatography was achieved using a Rezex RoA-organic acid H<sup>&#x2b;</sup> (8%) resin-based column preceded by a SecurityGuard guard cartridge (Phenomenex) held at 80&#xb0;C with 0.1% formic acid as the mobile phase. The temperature of the autosampler was kept at 6&#xb0;C, the injection volume was 20&#xa0;&#xb5;L, and an isocratic flow of 0.4&#xa0;mL&#xa0;min<sup>&#x2212;1</sup> was adjusted. Peak areas were corrected for the contribution of all naturally abundant isotopes using the software IsoCor (version 2.2.0) (<xref ref-type="bibr" rid="B35">Millard et al., 2012</xref>).</p>
</sec>
<sec id="s2-11">
<title>2.11 Computational methods</title>
<p>Multiple sequence alignment of NAD(P)H-dependent malate dehydrogenases and lactate dehydrogenases was performed using MAFFT (v 7.525) provided by EMBL-EBI (<xref ref-type="bibr" rid="B34">Madeira et al., 2024</xref>). UniProt identifiers of all proteins used in the alignment are listed in the supplementary material. Structure alignments were performed in PyMol v2.5.1 (<ext-link ext-link-type="uri" xlink:href="http://www.pymol.org/pymol">http://www.pymol.org/pymol</ext-link>). Three-dimensional structures were retrieved from the Protein Data Bank (PDB) or predicted with AlphaFold Colab (<xref ref-type="bibr" rid="B27">Jumper et al., 2021</xref>).</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>3 Results</title>
<sec id="s3-1">
<title>3.1 Strategy for the design of NADPH-dependent OHB reductase activity</title>
<p>We have previously engineered a highly active OHB reductase using the NAD<sup>&#x2b;</sup>-dependent (L)-malate dehydrogenase from <italic>E. coli</italic> (Ec.Mdh; UniProtKB code <ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/uniprotkb/P61889/entry">P61889</ext-link>) as a template enzyme. The best-performing variant, Ec.Mdh<sup>5Q</sup>, contains five point mutations (I12V:R81A:M85Q:D86S:G179D) and displays a 108-fold higher catalytic efficiency with NADH than with NADPH (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Because the typical intracellular ratios of [NAD(P)H]/[NAD(P)] in <italic>E. coli</italic> (<xref ref-type="bibr" rid="B2">Bennett et al., 2009</xref>) indicate that NADPH should be preferentially used as a cofactor in reduction processes under aerobic conditions, we set out to engineer an NADPH-dependent OHB reductase using Ec.Mdh<sup>5Q</sup> as the template enzyme.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Specific activity of Ec.Mdh<sup>5Q</sup> on OHB with NAD(P)H and 3D-protein structures with NAD<sup>&#x2b;</sup> or NADP<sup>&#x2b;</sup>. <bold>(A)</bold> Catalytic efficiency (k<sub>cat,app</sub>/K<sub>M,app</sub>) of Ec.Mdh<sup>5Q</sup> with NAD(P)H. Enzymatic activity was measured with purified enzyme at 37&#xb0;C and pH 7.0 in 96-well flat-bottomed microtiter plates with 2&#xa0;mM OHB and 0.25&#xa0;mM NAD(P)H. The reactions were followed by monitoring the NAD(P)H absorption at 340&#xa0;nm. Error bars indicate the standard deviation of the mean (n &#x3d; 2). <bold>(B)</bold> X-ray structure of Ec.Mdh with bound NAD<sup>&#x2b;</sup> (Pdb code: 1emd). Side chains of amino acids in the selectivity control loop are shown (positions 34&#x2013;38). <bold>(C)</bold> X-ray structure of Ec.Mdh with superimposed NADP<sup>&#x2b;</sup>. The figure was generated by the structural alignment of Ec.Mdh with bound NAD (Pdb code: 1emd) and the malate dehydrogenase from <italic>Flaveria bidentis</italic> (Fb.Mdh) with bound NADP (Pdb code: 1civ). The structures of Fb-Mdh and NAD were omitted from the representation. <bold>(D)</bold> Model structure of Ec.Mdh D34G:I35S with superimposed NADP<sup>&#x2b;</sup>. The figure was generated by structural alignment of the mutant enzyme model [generated with AlphaFold Colab (<xref ref-type="bibr" rid="B27">Jumper et al., 2021</xref>); mutations relative to wt enzyme are marked in violet] and the crystal structure of Fb.Mdh with bound NADP. Subfigures <bold>(B&#x2013;D)</bold> were generated in PyMol v2.5.1 (<ext-link ext-link-type="uri" xlink:href="http://www.pymol.org/pymol">http://www.pymol.org/pymol</ext-link>). The distance between selected residues is shown in &#xc5;. The carbon ribbon of cofactors NAD(P)<sup>&#x2b;</sup> is shown in pale yellow. The color scheme of NAD(P)<sup>&#x2b;</sup> and relevant amino acid side chains (position 34&#x2013;38) is oxygen &#x2013; red, nitrogen &#x2013; blue, and sulfur &#x2013; orange.</p>
</caption>
<graphic xlink:href="fbioe-13-1504785-g002.tif"/>
</fig>
<p>NAD<sup>&#x2b;</sup>-dependent (L)-malate dehydrogenases (cytosolic; Mdh type 1 family) belong to the large superfamily of (L)-Mdh/(L)-Ldh enzymes, which further includes NADP<sup>&#x2b;</sup>-dependent enzymes of identical function (chloroplastic; Mdh type 2 family) and NAD<sup>&#x2b;</sup>-dependent (L)-lactate dehydrogenases (Ldh). Multiple sequence alignments between several members of the superfamily of Mdh and Ldh enzymes revealed a strong conservation of the primary protein structure (<xref ref-type="sec" rid="s10">Supplementary Figure S1</xref>). Previous studies elucidated the crucial role of a loop region in a conserved cofactor binding motif of the Rossman fold for cofactor discrimination (<xref ref-type="bibr" rid="B26">Holmberg et al., 1999</xref>; <xref ref-type="bibr" rid="B37">Nishiyama et al., 1993</xref>; <xref ref-type="bibr" rid="B18">Feeney et al., 1990</xref>; <xref ref-type="bibr" rid="B40">Rossmann et al., 1974</xref>). Multiple sequence alignments showed that this region corresponds to the amino acid residues at positions 34 and 35 in Ec.Mdh (<xref ref-type="sec" rid="s10">Supplementary Figure S1</xref>). Of crucial interest in Ec.Mdh is the active site residue Asp34, which is pivotal for conferring cofactor specificity because its negative charge has previously been shown to result in electrostatic repulsion of the 2&#x2032;-phosphate group of NADP(H) (<xref ref-type="bibr" rid="B37">Nishiyama et al., 1993</xref>; <xref ref-type="bibr" rid="B18">Feeney et al., 1990</xref>). Visual inspection of the X-ray crystal structure of Ec.Mdh (PDB code with bound NAD<sup>&#x2b;</sup>: 1emd, <xref ref-type="fig" rid="F2">Figure 2B</xref>) bound with superimposed NADPH (<xref ref-type="fig" rid="F2">Figure 2C</xref>) further revealed a potential steric clash between the aspartate residue at position 34 and the 2&#x2032;-phosphate moiety of NADPH. Multiple sequence alignment analyses showed strict conservation at the corresponding position in NADP<sup>&#x2b;</sup>-dependent malate dehydrogenases with a glycine residue (<xref ref-type="sec" rid="s10">Supplementary Figure S1</xref>). Replacement of Asp34 residue in Ec.Mdh by the smaller and uncharged residue glycine, therefore, seemed crucial to accommodate the larger NADP(H) and to remove the unfavorable electrostatic interaction with NADP(H). In addition, residue Ile35 is of interest for switching the cofactor preference of Ec.Mdh. Due to its close proximity to the 2&#x2032;-phosphate group of NADPH (<xref ref-type="bibr" rid="B24">Hall and Banaszak, 1993</xref>), the amino acid residue located at position 35 is prone to form an electrostatic interaction or a hydrogen bond with the cofactor. Multiple sequence alignment of natural NADPH-dependent Mdh enzymes reveals complete conservation of a potentially hydrogen-bond donating serine residue at the position corresponding to Ile35 in Ec.Mdh. Therefore, we hypothesized that the isoleucine residue at position 35 should be exchanged for serine. This idea was complemented by the structure-guided web tool CSR-salad (<xref ref-type="bibr" rid="B7">Cahn et al., 2017</xref>), which suggested an exchange of Ile35 by positively charged residues (Lys, Arg) or other polar uncharged amino acids (Thr) to allow for an electrostatic or polar interaction with the 2&#x2032;-phosphate group of NADPH. Visual inspection of the predicted 3D structure of a respective Ec.Mdh D34G:I35S double mutant bound with NADP<sup>&#x2b;</sup> confirms the predicted absence of steric clashes in the selectivity control loop (<xref ref-type="fig" rid="F2">Figure 2D</xref>).</p>
</sec>
<sec id="s3-2">
<title>3.2 <italic>In vitro</italic> analysis of OHB reductase mutants</title>
<p>Point mutations to switch cofactor preference were stepwise introduced into the <italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup> gene by site-directed mutagenesis. The constructed N-terminally 6x-His-tagged variants were expressed from pET28a vectors transformed in <italic>E. coli</italic> BL21(DE3) cells. After purification, the specific activity of the purified variants was first quantified in the presence of OHB (2&#xa0;mM) and either NADH or NADPH (0.25&#xa0;mM) as cofactor. As shown in <xref ref-type="fig" rid="F3">Figure 3</xref>, the template enzyme Ec.Mdh<sup>5Q</sup> was highly active on OHB with NADH as a co-substrate (68 &#xb1; 4&#xa0;U&#xa0;mg<sup>&#x2212;1</sup>) but displayed low activity in the presence of NADPH (4 &#xb1; 0.2&#xa0;U&#xa0;mg<sup>&#x2212;1</sup>). For all of the engineered mutants, the cofactor preference (here defined as v<sub>(NADPH)</sub>/v<sub>(NADH)</sub>) was found to be altered. Replacement of the Asp34 residue by glycine resulted in comparable OHB reductase activity in the presence of both cofactors (v<sub>(NADH)</sub> &#x3d; 23 &#xb1; 2&#xa0;U&#xa0;mg<sup>&#x2212;1</sup>, v<sub>(NADPH)</sub> &#x3d; 35 &#xb1; 3&#xa0;U&#xa0;mg<sup>&#x2212;1</sup>), possibly indicating dual cofactor preference. The additional substitution of isoleucine at position 35 by serine, threonine, lysine, or arginine resulted in at least 2.5-fold higher activities in the presence of NADPH than NADH. With 64 &#xb1; 4.5&#xa0;U&#xa0;mg<sup>&#x2212;1</sup>, the specific OHB reductase activity of Ec.Mdh<sup>5Q</sup> D34G:I35R (hereafter abbreviated as Ec.Mdh<sup>7Q</sup>) with NADPH as a cofactor was nearly six-fold higher than with NADH (12 &#xb1; 0.02&#xa0;U&#xa0;mg<sup>&#x2212;1</sup>). The mutant variant showed a similar specific activity on OHB when compared to that of Ec.Mdh<sup>5Q</sup>. Thus, Ec.Mdh<sup>7Q</sup> was identified as the most promising NADPH-dependent OHB reductase enzyme, and its kinetic parameters on both cofactors and OHB were determined and compared to those of Ec.Mdh<sup>5Q</sup>.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Specific NAD(P)H-dependent OHB reductase activity of engineered variants derived from Ec.Mdh<sup>5Q</sup>. The enzymes were produced from <italic>E. coli</italic> BL21 (DE3) harboring the respective pET28a expression vectors cultivated in 50&#xa0;mL LB. Heterologous expression was induced at OD<sub>600</sub> of 0.6 with 1&#xa0;mM IPTG. Protein expression was carried out until OD<sub>600</sub> &#x3d; 2 was reached. Enzymatic assays were performed with purified enzyme at 37&#xb0;C and pH 7.0 in 96-well flat-bottomed microtiter plates with 2&#xa0;mM OHB and 0.25&#xa0;mM NAD(P)H. The reactions were followed by monitoring the NAD(P)H absorption at 340&#xa0;nm. Error bars indicate the standard deviation of the mean (n &#x3d; 2).</p>
</caption>
<graphic xlink:href="fbioe-13-1504785-g003.tif"/>
</fig>
<p>The kinetic parameters of both enzyme variants are summarized in <xref ref-type="table" rid="T3">Table 3</xref>. The engineered variant Ec.Mdh<sup>7Q</sup> exhibited more than three orders of magnitude higher specificity (defined as (k<sub>cat</sub>/K<sub>m(NADPH)</sub>)/(k<sub>cat</sub>/K<sub>m(NADH)</sub>) for NADPH than Ec.Mdh<sup>5Q</sup> (16 and 0.01, respectively). No loss in OHB affinity or impairment of the overall catalytic efficiency ((k<sub>cat</sub>/K<sub>m</sub>)<sub>OHB</sub> &#xd7; (k<sub>cat</sub>/K<sub>m</sub>)<sub>NAD(P)H</sub>) was observed. We observed uncompetitive substrate inhibition of Ec.Mdh<sup>7Q</sup> by OHB (K<sub>i</sub> &#x3d; 5.5 &#xb1; 0.5&#xa0;mM). Substrate inhibition was found to be stronger than for Ec.Mdh<sup>5Q</sup> (K<sub>i</sub> &#x3d; 31.9&#xa0;mM &#xb1; 5.6&#xa0;mM) (<xref ref-type="bibr" rid="B21">Fraz&#xe3;o et al., 2018</xref>).</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Kinetic analysis of OHB reductases Ec.Mdh<sup>5Q</sup> and Ec.Mdh<sup>7Q</sup>.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Enzyme</th>
<th align="left">Ec.Mdh<sup>5Q</sup>
</th>
<th align="left">Ec.Mdh<sup>7Q</sup>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td colspan="3" align="left">NADH<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref>
</td>
</tr>
<tr>
<td align="left">V<sub>max,app</sub> (U&#xa0;mg<sup>&#x2212;1</sup>)</td>
<td align="left">67.68 (&#xb1;3.12)</td>
<td align="left">20.02 (&#xb1;1.99)</td>
</tr>
<tr>
<td align="left">k<sub>cat,app</sub> (s<sup>&#x2212;1</sup>)</td>
<td align="left">36.48 (&#xb1;1.68)</td>
<td align="left">10.79 (&#xb1;1.07)</td>
</tr>
<tr>
<td align="left">K<sub>m,app</sub> (mM)</td>
<td align="left">0.04 (&#xb1;0.004)</td>
<td align="left">0.27 (&#xb1;0.04)</td>
</tr>
<tr>
<td align="left">k<sub>cat,app</sub>/K<sub>m,app</sub> (mM<sup>&#x2212;1</sup>&#xa0;s<sup>&#x2212;1</sup>)</td>
<td align="left">1,027.40 (&#xb1;67.46)</td>
<td align="left">40.35 (&#xb1;1.71)</td>
</tr>
<tr>
<td colspan="3" align="left">NADPH<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref>
</td>
</tr>
<tr>
<td align="left">V<sub>max,app</sub> (U&#xa0;mg<sup>&#x2212;1</sup>)</td>
<td align="left">5.56 (&#xb1;0.64)</td>
<td align="left">118.80 (&#xb1;18.5)</td>
</tr>
<tr>
<td align="left">k<sub>cat,app</sub> (s<sup>&#x2212;1</sup>)</td>
<td align="left">2.99 (&#xb1;0.35)</td>
<td align="left">64.03 (&#xb1;9.97)</td>
</tr>
<tr>
<td align="left">K<sub>m,app</sub> (mM)</td>
<td align="left">0.32 (&#xb1;0.04)</td>
<td align="left">0.10 (&#xb1;0.03)</td>
</tr>
<tr>
<td align="left">k<sub>cat,app</sub>/K<sub>m,app</sub> (mM<sup>&#x2212;1</sup>&#xa0;s<sup>&#x2212;1</sup>)</td>
<td align="left">9.50 (&#xb1;0.05)</td>
<td align="left">645.47 (&#xb1;76.25)</td>
</tr>
<tr>
<td colspan="3" align="left">OHB<xref ref-type="table-fn" rid="Tfn2">
<sup>b</sup>
</xref>
</td>
</tr>
<tr>
<td align="left">V<sub>max,app</sub> (U&#xa0;mg<sup>&#x2212;1</sup>)</td>
<td align="left">138.50 (&#xb1;10.45)</td>
<td align="left">154.80 (&#xb1;6.30)</td>
</tr>
<tr>
<td align="left">k<sub>cat,app</sub> (s<sup>&#x2212;1</sup>)</td>
<td align="left">74.89 (&#xb1;5.63)</td>
<td align="left">83.43 (&#xb1;3.40)</td>
</tr>
<tr>
<td align="left">K<sub>m,app</sub> (mM)</td>
<td align="left">1.84 (&#xb1;0.50)</td>
<td align="left">1.08 (&#xb1;0.19)</td>
</tr>
<tr>
<td align="left">K<sub>i</sub> (mM)</td>
<td align="left">31.9 (&#xb1;5.6)<xref ref-type="table-fn" rid="Tfn3">
<sup>c</sup>
</xref>
</td>
<td align="left">5.45 (&#xb1;0.48)</td>
</tr>
<tr>
<td align="left">k<sub>cat,app</sub>/K<sub>m,app</sub> (mM<sup>&#x2212;1</sup>&#xa0;s<sup>&#x2212;1</sup>)</td>
<td align="left">44.91 (&#xb1;15.18)</td>
<td align="left">80.29 (&#xb1;17.27)</td>
</tr>
<tr>
<td colspan="3" align="left">Specificity</td>
</tr>
<tr>
<td align="left">(k<sub>cat,app</sub>/K<sub>m,app</sub>)<sub>NADPH</sub>/(k<sub>cat,app</sub>/K<sub>m,app</sub>)<sub>NADH</sub>
</td>
<td align="left">0.01</td>
<td align="left">16.00</td>
</tr>
<tr>
<td colspan="3" align="left">Overall catalytic efficiency</td>
</tr>
<tr>
<td align="left">(k<sub>cat,app</sub>/K<sub>m,app</sub>)<sub>OHB</sub> &#xd7; (k<sub>cat,app</sub>/K<sub>m,app</sub>)<sub>NAD(P)H</sub>
</td>
<td align="left">46,136</td>
<td align="left">51,823</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="Tfn1">
<label>
<sup>a</sup>
</label>
<p>Specific OHB reductase activities were determined at fixed concentrations of substrate (OHB, 2&#xa0;mM) and variable concentrations of NAD(P)H (1&#x2013;0.03&#xa0;mM).</p>
</fn>
<fn id="Tfn2">
<label>
<sup>b</sup>
</label>
<p>Specific OHB reductase activities were determined at fixed concentrations (0.25&#xa0;mM) of the preferred co-substrate NAD(P)H and variable amounts of OHB (10&#x2013;0.005&#xa0;mM).</p>
</fn>
<fn id="Tfn3">
<label>
<sup>c</sup>
</label>
<p>
<xref ref-type="bibr" rid="B21">Fraz&#xe3;o et al. (2018)</xref>.</p>
</fn>
<fn>
<p>Apparent kinetic constants (K<sub>m,app</sub>, V<sub>max,app</sub>) were estimated by fitting the experimental data to the Michaelis&#x2013;Menten model using non-linear regression unless enzymes displayed substrate inhibition kinetics (Curve fitting tool, MATLAB R2021a). To calculate the apparent catalytic constant k<sub>cat</sub>,<sub>app</sub>, the molecular weight of one subunit of Ec.Mdh (32.337&#xa0;kDa) was considered. Specificity and efficiency were calculated based on mean k<sub>cat,app</sub> and K<sub>m,app</sub> values. Enzyme assays were performed in biological duplicates. Ec.Mdh<sup>5Q</sup> contains mutations I12V:R81A:M85Q:D86S:G179D.</p>
</fn>
<fn>
<p>Ec.Mdh<sup>7Q</sup> additionally contains mutations D34G:I35R.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3-3">
<title>3.3 DHB production using NADPH-dependent OHB reductase</title>
<p>Next, the <italic>in vivo</italic> performance of the NADPH-dependent OHB reductase Ec.Mdh<sup>7Q</sup> for DHB biosynthesis was investigated. To achieve DHB production from glucose, we selected <italic>E. coli</italic> MG1655 <italic>&#x394;thrB &#x394;metA &#x394;ldhA</italic> as a production host to ensure a sufficient supply of the homoserine precursor. The host was then equipped with a DHB pathway consisting of homoserine transaminase activity (catalyzed by Ec.AspC from <italic>E. coli</italic>), and NAD(P)H-dependent OHB reductase activity (either Ec.Mdh<sup>5Q</sup> or Ec.Mdh<sup>7Q</sup>) expressed from a medium-copy plasmid pZA23 under the control of the ITPG-inducible P<sub>A1lacO-1</sub> promoter. Constructed plasmids additionally carried threonine-insensitive bifunctional aspartate kinase/homoserine dehydrogenase (Ec.ThrA<sub>S345F</sub>) and the aspartate/malate insensitive phosphoenolpyruvate carboxylase variant Ec.Ppc<sub>K620S</sub> (<xref ref-type="bibr" rid="B21">Fraz&#xe3;o et al., 2018</xref>) (see the metabolic setting in <xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<p>Producer strains were cultivated in 25&#xa0;mL M9 mineral medium containing 20&#xa0;g&#xa0;L<sup>&#x2212;1</sup> glucose. (L)-methionine and (L)-threonine were added to the medium (at a final concentration of 0.2&#xa0;g&#xa0;L<sup>&#x2212;1</sup> each) to compensate for the host strain&#x2019;s auxotrophies. Expression of pathway genes was induced by IPTG (1&#xa0;mM) at the mid-exponential phase, and DHB production was quantified after 24&#xa0;h of cell cultivation. Upon expression of Ec.Mdh<sup>5Q</sup>, we found the culture supernatant to contain 7.0 &#xb1; 0.5&#xa0;mM DHB (EcHS1, <xref ref-type="fig" rid="F4">Figure 4</xref>), reaching a product yield of 0.10 &#xb1; 0.004 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup> and a volumetric productivity of 0.29 &#xb1; 0.02 mmol<sub>DHB</sub> L<sup>&#x2212;1</sup>&#xa0;h<sup>&#x2212;1</sup>. Strain EcHS2 expressing Ec.Mdh<sup>7Q</sup> was able to produce 7.5 &#xb1; 0.6&#xa0;mM DHB. Because only a modest increase in DHB production was observed with NADPH-dependent OHB reductase, we speculated at this stage that homoserine transaminase activity was limiting. Indeed, purified Ec.AspC enzyme has previously been shown to display only low <italic>in vitro</italic> activity on (L)-homoserine (0.082&#xa0;U&#xa0;mg<sup>&#x2212;1</sup>), and it could not be saturated at substrate concentrations of up to 50&#xa0;mM (L)-homoserine (<xref ref-type="bibr" rid="B45">Walther et al., 2017a</xref>; <xref ref-type="bibr" rid="B47">Walther et al., 2017b</xref>). Crucially, however, Bouzon and co-workers (2017) previously disclosed a homoserine transaminase (Ec.AlaC<sub>A142P:Y275D</sub>) with a much higher affinity for homoserine (K<sub>m</sub> &#x3d; 1.7&#xa0;mM). Therefore, we reanalyzed the effect of the different OHB reductases when co-expressing Ec.AlaC<sub>A142P:Y275D</sub> in the producer strains. Indeed, co-expression of Ec.Mdh<sup>5Q</sup> and Ec.AlaC<sub>A142P:Y275D</sub> (EcHS3) led to a DHB titer of 13.8 &#xb1; 0.5&#xa0;mM, which constitutes roughly a 2-fold improvement over the use of Ec.AspC. This result confirms the homoserine transaminase activity of Ec.AspC as a rate-limiting step in the pathway, and we retained the transaminase Ec.AlaC<sub>A142P:Y275D</sub> for all subsequent experiments. Replacement of Ec.Mdh<sup>5Q</sup> by NADPH-dependent OHB reductase led to the production of 17.2 &#xb1; 0.2&#xa0;mM (EcHS4), which represents a 25% improvement compared to the corresponding strain with the NADH-dependent variant. By co-expressing <italic>Ec.alaC</italic>
<sub>
<italic>A142P:Y275D</italic>
</sub> and <italic>Ec.mdh</italic>
<sup>
<italic>7Q</italic>
</sup> genes, a maximum DHB product yield of 0.20 &#xb1; 0.005 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup> and a volumetric productivity of 0.72 &#xb1; 0.01 mmol<sub>DHB</sub> L<sup>&#x2212;1</sup>&#xa0;h<sup>&#x2212;1</sup> were achieved. Analysis of the enantiomeric purity of DHB revealed the presence of only the L-form of the organic acid (data not shown).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>DHB concentration and yield after 24&#xa0;h cultivation of engineered production strains. All strains are derived from the parental strain <italic>E. coli</italic> MG1655 <italic>&#x394;thrB &#x394;metA &#x394;ldhA</italic>, which was transformed with medium-copy DHB production plasmids expressing homoserine transaminase (<italic>Ec.aspC or Ec.alaC</italic>
<sub>
<italic>A142P:Y275D</italic>
</sub>) and OHB reductase (<italic>Ec.Mdh</italic>
<sub>
<italic>5Q</italic>
</sub> or <italic>Ec.Mdh</italic>
<sub>
<italic>7Q</italic>
</sub>). All plasmids further carry <italic>Ec.thrA</italic>
<sub>
<italic>S345F</italic>
</sub> and <italic>Ec.ppc</italic>
<sub>
<italic>K620S</italic>
</sub>. Cultivation was performed at 37&#xb0;C and 220&#xa0;rpm in 250&#xa0;mL baffled flasks containing 25&#xa0;mL M9 medium with 20&#xa0;g&#xa0;L<sup>&#x2212;1</sup> glucose, supplemented with 0.2&#xa0;g&#xa0;L<sup>&#x2212;1</sup> (L)-methionine and 0.2&#xa0;g&#xa0;L<sup>&#x2212;1</sup> (L)-threonine. The expression of pathway genes was induced at an OD<sub>600</sub> of 0.6 with 1&#xa0;mM IPTG. DHB titers and yields after 24&#xa0;h of cultivation are shown. The experiments were performed in biological duplicates. Error bars indicate the standard deviation of the mean.</p>
</caption>
<graphic xlink:href="fbioe-13-1504785-g004.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>3.4 Construction of NADPH over-producing strain for improved DHB production</title>
<p>To demonstrate the full potential of NADPH-dependent OHB reductase toward DHB production, we next engineered the host strain <italic>E. coli</italic> MG1655 <italic>&#x394;thrB &#x394;metA &#x394;ldhA</italic> toward increased NADPH supply. We selected multiple chromosomal targets previously shown to increase the intracellular availability of NADPH, including the deletion of the <italic>Ec.pfkA</italic> gene (encoding 6-phosphofructokinase I) to enhance flux through the pentose phosphate pathway (<xref ref-type="bibr" rid="B11">Chin and Cirino, 2011</xref>). We further altered the expression of the transhydrogenase system toward the formation of NADPH by deleting soluble pyridine nucleotide transhydrogenase Ec.SthA (NAD<sup>&#x2b;</sup> &#x2b; NADPH &#x2192; NADH &#x2b; NADP<sup>&#x2b;</sup>; <xref ref-type="bibr" rid="B3">Boonstra et al., 1999</xref>; <xref ref-type="bibr" rid="B41">Sauer et al., 2004</xref>) and/or overexpressing membrane-bound pyridine nucleotide transhydrogenase Ec.PntAB (NADH &#x2b; NADP<sup>&#x2b;</sup> &#x2192; NAD<sup>&#x2b;</sup> &#x2b; NADPH; <xref ref-type="bibr" rid="B13">Clarke et al., 1986</xref>; <xref ref-type="bibr" rid="B41">Sauer et al., 2004</xref>). The resulting host strains were then used to characterize the impact of increased NADPH availability on DHB production with the NADPH-dependent OHB reductase. To investigate potential effects on DHB production that may be caused by altered homoserine availability, we additionally tested Ec.Mdh<sup>5Q</sup>.</p>
<p>After 24&#xa0;h of cultivation in glucose-containing mineral medium, the producer strains with the chromosomal deletion of the <italic>Ec.pfkA</italic> gene and expressing the NADH-dependent <italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup> (EcHS5) exhibited a severe drop of both DHB concentration and yield when compared to the reference strain EcHS3 (<xref ref-type="fig" rid="F5">Figure 5</xref>). This may be related to the observed growth defect caused by <italic>Ec.pfkA</italic> deletion (data not shown). With EcHS6 deleted for <italic>Ec.sthA</italic>, the DHB yield was equal to 0.19 &#xb1; 0.03 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup>, which corresponds to a 19% increase when compared to reference strain EcHS3 with a yield of 0.16&#xa0;mol &#xb1; 0.001 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup>. Upon chromosomal overexpression of <italic>Ec.pntAB</italic> (EcHS7), the product yield was further increased to 0.21 &#xb1; 0.007 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup>, which corresponds to a total increase of 30% compared to the reference strain (EcHS3). The additional deletion of <italic>Ec.sthA</italic> did not provide an advantage and indeed caused the DHB yield to drop to 0.18 &#xb1; 0.008 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup>.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>DHB concentration and yield after 24&#xa0;h cultivation of engineered production strains with increased NADPH availability. All strains were derived from the parental strain <italic>E. coli</italic> MG1655 <italic>&#x394;thrB &#x394;metA &#x394;ldhA</italic>, which was transformed with medium-copy DHB production plasmids expressing homoserine transaminase (<italic>Ec.alaC</italic>
<sub>
<italic>A142P:Y275D</italic>
</sub>) and OHB reductase (<italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup> or <italic>Ec.mdh</italic>
<sup>
<italic>7Q</italic>
</sup>). All plasmids further carried <italic>Ec.thrA</italic>
<sub>
<italic>S345F</italic>
</sub> and <italic>Ec.ppc</italic>
<sub>
<italic>K620S</italic>
</sub>
<italic>.</italic> Cultivation was performed at 37&#xb0;C and 220&#xa0;rpm in 250-mL baffled flasks containing 25&#xa0;mL M9 medium with 20&#xa0;g&#xa0;L<sup>&#x2212;1</sup> glucose, supplemented with 0.2&#xa0;g&#xa0;L<sup>&#x2212;1</sup> (L)-methionine and 0.2&#xa0;g&#xa0;L<sup>&#x2212;1</sup> (L)-threonine. Expression of pathway genes was induced at an OD<sub>600</sub> of 0.6 with 1&#xa0;mM IPTG. DHB titers and yields after 24&#xa0;h of cultivation are shown. The experiments were performed in biological duplicates. Error bars indicate the standard deviation of the mean.</p>
</caption>
<graphic xlink:href="fbioe-13-1504785-g005.tif"/>
</fig>
<p>The production strains expressing <italic>Ec.mdh</italic>
<sup>
<italic>7Q</italic>
</sup> displayed similar tendencies as the strains expressing <italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup>. However, the positive effect on DHB production upon chromosomal overexpression of <italic>Ec.pntAB</italic> was enhanced, yielding 0.25 &#xb1; 0.01 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup> after 24&#xa0;h cultivation of EcHS11. Thus, increased NADPH availability via chromosomal overexpression of <italic>pntAB</italic> promoted DHB synthesis, particularly in the presence of the engineered NADPH-dependent enzyme variant.</p>
<p>To sum up, by co-expression of the improved homoserine transaminase (<italic>Ec.alaC</italic>
<sub>
<italic>A142P:Y275D</italic>
</sub>) with the NADPH-dependent OHB reductase <italic>Ec.mdh</italic>
<sup>
<italic>7Q</italic>
</sup> and by further modification of the production strain (<italic>Ec.pntAB</italic>
<sup>
<italic>proD</italic>
</sup>
<italic>)</italic>, it was possible to increase the DHB yield by 50% to 0.25 &#xb1; 0.01 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup> and reach a volumetric productivity of 0.83 &#xb1; 0.03 mmol<sub>DHB</sub> L<sup>&#x2212;1</sup>&#xa0;h<sup>&#x2212;1</sup> within 24&#xa0;h of batch cultivation of EcHS11.</p>
</sec>
<sec id="s3-5">
<title>3.5 Discussion</title>
<p>In previous work, we used a rational engineering approach to construct a highly active OHB reductase enzyme, catalyzing the last reaction step of the artificial homoserine-dependent DHB synthesis route (<xref ref-type="bibr" rid="B21">Fraz&#xe3;o et al., 2018</xref>). Because we used the NAD<sup>&#x2b;</sup>-dependent <italic>E. coli</italic> malate dehydrogenase (Ec.Mdh; UniProtKB code P61889) as a template to construct Ec.Mdh<sup>5Q</sup> (I12V:R81A:M85Q:D86S:G179D), the reduction of OHB in the synthetic pathway relied on NADH as a cofactor. However, typical intracellular ratios of [NAD(P)H]/[NAD(P)] in <italic>E. coli</italic> (<xref ref-type="bibr" rid="B2">Bennett et al., 2009</xref>) indicate that the use of a NADPH-dependent OHB reductase provides a thermodynamic advantage. In this study, we aimed to replace the currently used NADH-dependent OHB reductase by an enzyme with NADPH-dependent activity.</p>
<p>Oxidoreductases with nicotinamide cofactor dependency exhibit a strong preference for either NAD(H) or NADP(H) (<xref ref-type="bibr" rid="B8">Ch&#xe1;nique and Parra, 2018</xref>). In the large and complex (L)-malate/(L)-lactate dehydrogenase superfamily, most enzyme candidates of microbial origin rely on the NAD(H) cofactor system, typically showing only low residual activities with NADP(H) (<xref ref-type="bibr" rid="B44">Takahashi-&#xcd;&#xf1;iguez et al., 2016</xref>; <xref ref-type="bibr" rid="B5">Brochier-Armanet and Madern, 2021</xref>). Whereas naturally existing NADP(H)-dependent Ldhs have not yet been identified (<xref ref-type="bibr" rid="B39">Richter et al., 2011</xref>), NADP(H)-preferring Mdhs exist in chloroplasts (<xref ref-type="bibr" rid="B29">Lemaire et al., 1996</xref>). Indeed, we initially envisaged the construction of a NADPH-dependent OHB reductase using the NADP<sup>&#x2b;</sup>-dependent chloroplast malate dehydrogenase originating from <italic>Sorghum bicolor</italic> (Sb.chMdhP) as a template enzyme (<xref ref-type="bibr" rid="B14">Cr&#xe9;tin et al., 1990</xref>). Because we did not succeed in the production of a soluble, active enzyme variant in <italic>E. coli</italic>, we altered our strategy and instead focused on switching the cofactor specificity of previously reported NADH-dependent OHB reductase variant Ec.Mdh<sup>5Q</sup> toward NADPH.</p>
<p>Previous studies investigating the cofactor specificity of enzymes belonging to the (L)-malate/(L)-lactate dehydrogenase superfamily revealed that only a few amino acid residues are responsible for conferring the preference for either NAD(H) or NADP(H). In attempts to reverse the enzyme cofactor dependency, identifying crucial cofactor-discriminating key positions is usually followed by site-directed mutagenesis of the respective amino acid residues or a loop exchange approach (<xref ref-type="bibr" rid="B8">Ch&#xe1;nique and Parra, 2018</xref>). Our present study confirms the crucial importance of the amino acid residues at positions 34 and 35 in Ec.Mdh in conferring cofactor preference. Upon replacing Asp34 and Ile35 with glycine and arginine, respectively, the cofactor specificity of the mutant Ec.Mdh<sup>7Q</sup> was successfully altered from NADH to NADPH. Switching the cofactor specificity while maintaining comparable catalytic efficiency to that of the wild-type enzyme represents a significant challenge. In the majority of previous attempts of switching the cofactor specificity of oxidoreductases from NAD(H) to NADP(H), the catalytic efficiency of the mutant with NADP(H) was severely reduced, reaching less than 50% of the wild type&#x2019;s catalytic efficiency with NAD(H) (<xref ref-type="bibr" rid="B8">Ch&#xe1;nique and Parra, 2018</xref>). Although the catalytic efficiency of Ec.Mdh<sup>7Q</sup> with NADPH was also reduced in the context of this study, it still reached more than 60% of that of the template enzymes with NADH. Further engineering efforts should be made to fully recover the activity of Ec.Mdh<sup>7Q</sup> with NADPH compared to the template enzyme Ec.Mdh<sup>5Q</sup> with NADH. More relevant for <italic>in vivo</italic> DHB pathway operation using the NADPH-dependent variant, the overall catalytic efficiency for OHB reduction in the presence of the preferred cofactor defined as (k<sub>cat,app</sub>/K<sub>m,app</sub>)<sub>(OHB)</sub> &#xd7; (k<sub>cat,app</sub>/K<sub>m,app</sub>)<sub>(NAD(P)H)</sub> of the mutant Ec.Mdh<sup>7Q</sup> (on OHB with NADPH) was comparable to the template enzyme Ec.Mdh<sup>5Q</sup> (on OHB with NADH). Thus, the engineered Ec.Mdh<sup>7Q</sup> was a promising candidate for <italic>in vivo</italic> application.</p>
<p>When we first replaced the NADH-dependent OHB reductase with our engineered NADPH-dependent variant for <italic>in vivo</italic> DHB production via the homoserine-dependent pathway, a positive effect could not be observed. Thus, we speculated that our current transaminase, Ec.AspC, was limiting the pathway flux (<xref ref-type="fig" rid="F4">Figure 4</xref>). By exchanging Ec.AspC with the alanine aminotransferase double mutant Ec.AlaC<sub>A142P:Y275D</sub> (<xref ref-type="bibr" rid="B4">Bouzon et al., 2017</xref>) and co-expression with the NADH-dependent Ec.Mdh<sup>5Q</sup>, we could indeed show a two-fold improvement in DHB production, reaching a concentration of 13.8 &#xb1; 0.5&#xa0;mM. Upon co-expression of Ec.AlaC<sub>A142P:Y275D</sub> and Ec.Mdh<sup>7Q</sup>, we could even reach up to 17.2 &#xb1; 0.2&#xa0;mM DHB and a product yield of 0.20 &#xb1; 0.005 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup> after 24&#xa0;h of cultivation. The results show the superior <italic>in vivo</italic> performance of the engineered NADPH-dependent OHB reductase variant but also clearly indicate the crucial role of sufficient transaminase activity for efficient pathway operation. However, it must be considered that the affinity of the engineered OHB reductase variant for the synthetic substrate might still be insufficient (K<sub>m</sub> &#x3d; 1.08 &#xb1; 0.19&#xa0;mM), as intracellular OHB concentrations are expected to be in the range of sub-mM levels (<xref ref-type="bibr" rid="B45">Walther et al., 2017a</xref>). Due to the reversibility of the transaminase reaction and the high intracellular glutamate concentrations (<xref ref-type="bibr" rid="B2">Bennett et al., 2009</xref>), the availability of an effective OHB reductase with high affinity toward the synthetic substrate and high overall catalytic efficiency is crucial to shift the <italic>in vivo</italic> pathway flux in the direction of the target product DHB. Thus, further engineering might be required to reduce the K<sub>m</sub> of the engineered OHB reductase variant.</p>
<p>Several studies showed how increased NADPH availability resulted in higher yields and productivities of NADPH-dependent product formations. To show the full potential of our engineered NADPH-dependent OHB reductase, we engineered the host strain toward increased NADPH availability using common strategies, including chromosomal deletion of <italic>Ec.pfkA</italic> to increase the flux through the PPP, deletion of <italic>Ec.sthA</italic>, and chromosomal overexpression of <italic>Ec.pntAB</italic> (<xref ref-type="bibr" rid="B28">Kabus et al., 2007</xref>; <xref ref-type="bibr" rid="B38">Rathnasingh et al., 2012</xref>; <xref ref-type="bibr" rid="B42">Shi et al., 2013</xref>; <xref ref-type="bibr" rid="B15">Cui et al., 2014</xref>; <xref ref-type="bibr" rid="B6">Cabulong et al., 2019</xref>; <xref ref-type="bibr" rid="B25">Hao et al., 2020</xref>; <xref ref-type="bibr" rid="B9">Chen et al., 2024</xref>; <xref ref-type="bibr" rid="B49">Zhang et al., 2021</xref>; <xref ref-type="bibr" rid="B11">Chin and Cirino, 2011</xref>). To investigate the potential effects of increased precursor supply, we also evaluated DHB production in NADPH-overproducing host strains expressing the NADH-dependent OHB reductase <italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup>. Noticeably, we observed a 19% increased DHB yield in our producer strain EcHS5 deleted for <italic>sthA</italic>, expressing <italic>Ec.alaC</italic>
<sub>
<italic>A142P:Y275D</italic>
</sub> and <italic>Ec.mdh</italic>
<sup>
<italic>5Q</italic>
</sup> and a 25% yield increase in the strain EcHS6 overexpressing <italic>pntAB</italic> compared to the respective reference strain EcHS3 (0.16&#xa0;mol &#xb1;0.001 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup>). These improvements could possibly be ascribed to an enhancement of homoserine production, as two mol of NADPH are necessary to produce one mol of homoserine. However, the positive effect of engineering NADPH supply via <italic>pntAB</italic> overexpression was clearly strongest in the producer strain EcHS11 expressing the engineered NADPH-dependent <italic>Ec.mdh</italic>
<sup>
<italic>7Q</italic>
</sup>, reaching the highest DHB yield on glucose (0.25 &#xb1; 0.01 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup>) reported so far. Although much higher DHB yields starting from homoserine have been reported (0.94&#xa0;mol&#xa0;mol<sup>&#x2212;1</sup>) with high-cell densities in recent work of <xref ref-type="bibr" rid="B33">Liu et al. (2022)</xref>, such an approach requires the separate fermentation of L-homoserine from glucose, thereby increasing production costs. Furthermore, to the best of our knowledge, the authors did not report yields taking into account the use of the initial glucose substrate. In this study, we report a 50% increase in DHB yield with producer strain EcHS11, compared to the reference EcHS1 (0.10 &#xb1; 0.004 mol<sub>DHB</sub> mol<sub>Glucose</sub>
<sup>&#x2212;1</sup>). It would be worthwhile investigating whether DHB titers could be increased further through enhanced NADPH availability. In a previous study, <xref ref-type="bibr" rid="B36">Ng et al. (2015)</xref> presented a promising strategy to increase the NADPH regeneration rate in <italic>E. coli</italic> by 25-fold, based on the heterologous expression of a synthetic Entner&#x2013;Doudoroff pathway.</p>
<p>In a larger, more general context, our study shows how streamlining NADPH cofactor preference of the biosynthetic pathway (by enzyme engineering) and NADPH cofactor supply (by metabolic engineering) can increase the efficiency of aerobic biosyntheses of reduced compounds.</p>
</sec>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s4">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s10">Supplementary Material</xref>; further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="author-contributions" id="s5">
<title>Author contributions</title>
<p>NI: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &#x26; editing. LG: Investigation, Writing &#x2013; review &#x26; editing. CA: Investigation, Writing &#x2013; review &#x26; editing. TN: Investigation, Writing &#x2013; review &#x26; editing. TW: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &#x26; editing. CF: Conceptualization, Investigation, Methodology, Project administration, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &#x26; editing.</p>
</sec>
<sec sec-type="funding-information" id="s6">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by a grant from ERA-CoBioTech (ID: 20) awarded to TW. This project is co-funded by the European Union and co-financed from tax revenues on the basis of the budget adopted by the Saxon State Parliament (Project number 100549942). The LC/MS system was in part founded by the Deutsche Forschungsgemeinschaft (INST 269/792-1 FUGG).</p>
</sec>
<ack>
<p>The authors thank Prof. Jean-Marie Fran&#xe7;ois for the helpful discussions and for kindly providing the strain bWL1221.</p>
</ack>
<sec sec-type="COI-statement" id="s7">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s8">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s10">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fbioe.2025.1504785/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fbioe.2025.1504785/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baba</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Okumura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Baba</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Construction of <italic>Escherichia coli</italic> K-12 in-frame, single-gene knockout mutants: the Keio collection</article-title>. <source>Mol. Syst. Biol.</source> <volume>2</volume>, <fpage>2006.0008</fpage>. <pub-id pub-id-type="doi">10.1038/msb4100050</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennett</surname>
<given-names>B. D.</given-names>
</name>
<name>
<surname>Kimball</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Osterhout</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Van Dien</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Rabinowitz</surname>
<given-names>J. D.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Absolute metabolite concentrations and implied enzyme active site occupancy in <italic>Escherichia coli</italic>
</article-title>. <source>Nat. Chem. Biol.</source> <volume>5</volume> (<issue>8</issue>), <fpage>593</fpage>&#x2013;<lpage>599</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.186</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boonstra</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Wainwright</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bruce</surname>
<given-names>N. C.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>The UdhA gene of <italic>Escherichia coli</italic> encodes a soluble pyridine nucleotide transhydrogenase</article-title>. <source>J. Bacteriol.</source> <volume>181</volume> (<issue>3</issue>), <fpage>1030</fpage>&#x2013;<lpage>1034</lpage>. <pub-id pub-id-type="doi">10.1128/JB.181.3.1030-1034.1999</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bouzon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perret</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Loreau</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Delmas</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Perchat</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jean</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>A synthetic alternative to canonical one-carbon metabolism</article-title>. <source>ACS Synth. Biol.</source> <volume>6</volume> (<issue>8</issue>), <fpage>1520</fpage>&#x2013;<lpage>1533</lpage>. <pub-id pub-id-type="doi">10.1021/acssynbio.7b00029</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brochier-Armanet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Madern</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Phylogenetics and biochemistry elucidate the evolutionary link between L-malate and L-lactate dehydrogenases and disclose an intermediate group of sequences with mix functional properties</article-title>. <source>Biochimie</source> <volume>191</volume>, <fpage>140</fpage>&#x2013;<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1016/j.biochi.2021.08.004</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabulong</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Valdehuesa</surname>
<given-names>K. N. G.</given-names>
</name>
<name>
<surname>Ba&#xf1;ares</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>K. R. M.</given-names>
</name>
<name>
<surname>Nisola</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W. K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Improved cell growth and biosynthesis of glycolic acid by overexpression of membrane-bound pyridine nucleotide transhydrogenase</article-title>. <source>J. Industrial Microbiol. Biotechnol.</source> <volume>46</volume> (<issue>2</issue>), <fpage>159</fpage>&#x2013;<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1007/s10295-018-2117-2</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cahn</surname>
<given-names>J. K. B.</given-names>
</name>
<name>
<surname>Werlang</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Baumschlager</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brinkmann-Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mayo</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>F. H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>A general tool for engineering the NAD/NADP cofactor preference of oxidoreductases</article-title>. <source>ACS Synth. Biol.</source> <volume>6</volume> (<issue>2</issue>), <fpage>326</fpage>&#x2013;<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1021/acssynbio.6b00188</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ch&#xe1;nique</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Parra</surname>
<given-names>L. P.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Protein engineering for nicotinamide coenzyme specificity in oxidoreductases: attempts and challenges</article-title>. <source>Front. Microbiol.</source> <volume>9</volume>, <fpage>194</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2018.00194</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Balancing the AspC and AspA pathways of <italic>Escherichia coli</italic> by systematic metabolic engineering strategy for high-efficient L-homoserine production</article-title>. <source>ACS Synth. Biol.</source> <volume>13</volume>, <fpage>2457</fpage>&#x2013;<lpage>2469</lpage>. <pub-id pub-id-type="doi">10.1021/acssynbio.4c00208</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cherepanov</surname>
<given-names>P. P.</given-names>
</name>
<name>
<surname>Wilfried</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Gene disruption in <italic>Escherichia coli</italic>: TcR and KmR cassettes with the option of flp-catalyzed excision of the Antibiotic-resistance determinant</article-title>. <source>Gene</source> <volume>158</volume> (<issue>1</issue>), <fpage>9</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/0378-1119(95)00193-A</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chin</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Cirino</surname>
<given-names>P. C.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Improved NADPH supply for xylitol production by engineered <italic>Escherichia coli</italic> with glycolytic mutations</article-title>. <source>Biotechnol. Prog.</source> <volume>27</volume> (<issue>2</issue>), <fpage>333</fpage>&#x2013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1002/btpr.559</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Chmiel</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2018</year>). <source>Bioprozesstechnik</source>. <edition>4th edn</edition>, Editors <person-group person-group-type="editor">
<name>
<surname>Chmiel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takors</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Weuster-Botz</surname>
<given-names>D.</given-names>
</name>
</person-group> (<publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer Berlin Heidelberg</publisher-name>). <pub-id pub-id-type="doi">10.1007/978-3-662-54042-8</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Loo</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Gilliam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bragg</surname>
<given-names>P. D.</given-names>
</name>
</person-group> (<year>1986</year>). <article-title>Nucleotide sequence of the PntA and PntB genes encoding the pyridine nucleotide transhydrogenase of <italic>Escherichia coli</italic>
</article-title>. <source>Eur. J. Biochem.</source> <volume>158</volume> (<issue>3</issue>), <fpage>647</fpage>&#x2013;<lpage>653</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-1033.1986.tb09802.x</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cr&#xe9;tin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Luchetta</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Joly</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Decottignies</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lepiniec</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gadal</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>1990</year>). <article-title>Primary structure of Sorghum malate dehydrogenase (NADP) deduced from CDNA sequence</article-title>. <source>Eur. J. Biochem.</source> <volume>192</volume> (<issue>2</issue>), <fpage>299</fpage>&#x2013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-1033.1990.tb19227.x</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y. Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J. Z.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Production of shikimic acid from <italic>Escherichia coli</italic> through chemically inducible chromosomal evolution and cofactor metabolic engineering</article-title>. <source>Microb. Cell Factories</source> <volume>13</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1186/1475-2859-13-21</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Datsenko</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Wanner</surname>
<given-names>B. L.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>One-step inactivation of chromosomal genes in <italic>Escherichia coli</italic> K-12 using PCR products</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>97</volume> (<issue>12</issue>), <fpage>6640</fpage>&#x2013;<lpage>6645</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.120163297</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Rubin</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Sauer</surname>
<given-names>R. T.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Design, construction and characterization of a set of insulated bacterial promoters</article-title>. <source>Nucleic Acids Res.</source> <volume>39</volume> (<issue>3</issue>), <fpage>1131</fpage>&#x2013;<lpage>1141</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkq810</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feeney</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Holbrook</surname>
<given-names>J. J.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>A single amino acid substitution in lactate dehydrogenase improves the catalytic efficiency with an alternative coenzyme</article-title>. <source>Biochem. Biophysical Res. Commun.</source> <volume>166</volume> (<issue>2</issue>), <fpage>667</fpage>&#x2013;<lpage>672</lpage>. <pub-id pub-id-type="doi">10.1016/0006-291X(90)90861-G</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fran&#xe7;ois</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Progress advances in the production of bio-sourced methionine and its hydroxyl analogues</article-title>. <source>Biotechnol. Adv.</source> <volume>69</volume>, <fpage>108259</fpage>. <pub-id pub-id-type="doi">10.1016/j.biotechadv.2023.108259</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Frazao</surname>
<given-names>C. J. R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Refactoring metabolic pathways for synthon production from renew-able carbon sources</article-title>. <comment>Agricultural sciences</comment>. <publisher-name>INSA de Toulouse</publisher-name>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraz&#xe3;o</surname>
<given-names>C. J. R.</given-names>
</name>
<name>
<surname>Topham</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Malbert</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fran&#xe7;ois</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Rational engineering of a malate dehydrogenase for microbial production of 2,4-dihydroxybutyric acid via homoserine pathway</article-title>. <source>Biochem. J.</source> <volume>475</volume> (<issue>23</issue>), <fpage>3887</fpage>&#x2013;<lpage>3901</lpage>. <pub-id pub-id-type="doi">10.1042/BCJ20180765</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraz&#xe3;o</surname>
<given-names>C. J. R.</given-names>
</name>
<name>
<surname>Trichez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Serrano-Bataille</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dagkesamanskaia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Topham</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Construction of a synthetic pathway for the production of 1,3-propanediol from glucose</article-title>. <source>Sci. Rep.</source> <volume>9</volume> (<issue>1</issue>), <fpage>11576</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-48091-7</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraz&#xe3;o</surname>
<given-names>C. J. R.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kenny</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Construction of a synthetic metabolic pathway for biosynthesis of 2,4-dihydroxybutyric acid from ethylene glycol</article-title>. <source>Nat. Commun.</source> <volume>14</volume> (<issue>1</issue>), <fpage>1931</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-023-37558-x</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Banaszak</surname>
<given-names>L. J.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Crystal structure of a ternary complex of <italic>Escherichia coli</italic> malate dehydrogenase citrate and NAD at 1&#xb7;9 &#xc5; resolution</article-title>. <source>J. Mol. Biol.</source> <volume>232</volume>, <fpage>213</fpage>&#x2013;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1993.1377</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Men</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>High-yield production of L-valine in engineered <italic>Escherichia coli</italic> by a novel two-stage fermentation</article-title>. <source>Metab. Eng.</source> <volume>62</volume>, <fpage>198</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymben.2020.09.007</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmberg</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ryde</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>B&#xfc;low</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Redesign of the coenzyme specificity in L-lactate dehydrogenase from Bacillus stearothermophilus using site-directed mutagenesis and media engineering</article-title>. <source>Protein Eng.</source> <volume>12</volume> (<issue>10</issue>), <fpage>851</fpage>&#x2013;<lpage>856</lpage>. <pub-id pub-id-type="doi">10.1093/protein/12.10.851</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jumper</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pritzel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Figurnov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ronneberger</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Highly accurate protein structure prediction with AlphaFold</article-title>. <source>Nature</source> <volume>596</volume> (<issue>7873</issue>), <fpage>583</fpage>&#x2013;<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kabus</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Georgi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wendisch</surname>
<given-names>V. F.</given-names>
</name>
<name>
<surname>Bott</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Expression of the <italic>Escherichia coli</italic> PntAB genes encoding a membrane-bound transhydrogenase in corynebacterium glutamicum improves l-lysine formation</article-title>. <source>Appl. Microbiol. Biotechnol.</source> <volume>75</volume> (<issue>1</issue>), <fpage>47</fpage>&#x2013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-006-0804-9</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemaire</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miginiac-Maslow</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Decottignies</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>The catalytic site of chloroplastic NADP-dependent malate dehydrogenase contains a his/Asp pair</article-title>. <source>Eur. J. Biochem.</source> <volume>236</volume> (<issue>3</issue>), <fpage>947</fpage>&#x2013;<lpage>952</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-1033.1996.00947.x</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lennox</surname>
<given-names>E. S.</given-names>
</name>
</person-group> (<year>1955</year>). <article-title>Transduction of linked genetic characters of the host by bacteriophage P1</article-title>. <source>Virology</source> <volume>1</volume> (<issue>2</issue>), <fpage>190</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1016/0042-6822(55)90016-7</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Design and construction of a non-natural malate to 1,2,4-butanetriol pathway creates possibility to produce 1,2,4-butanetriol from glucose</article-title>. <source>Sci. Rep.</source> <volume>4</volume> (<issue>1</issue>), <fpage>5541</fpage>. <pub-id pub-id-type="doi">10.1038/srep05541</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Xu</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Comparison of individual component deletions in a glucose-specific phosphotransferase system revealed their different applications</article-title>. <source>Sci. Rep.</source> <volume>5</volume> (<issue>1</issue>), <fpage>13200</fpage>. <pub-id pub-id-type="doi">10.1038/srep13200</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Efficient production of 2,4-dihydroxybutyrate from l -homoserine by the designed cofactor self-sufficient route</article-title>. <source>ACS Sustain. Chem. Eng.</source> <volume>10</volume>, <fpage>14361</fpage>&#x2013;<lpage>14369</lpage>. <pub-id pub-id-type="doi">10.1021/acssuschemeng.2c05012</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madeira</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Madhusoodanan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Eusebi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Niewielska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tivey</surname>
<given-names>A. R. N.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>The EMBL-EBI job dispatcher sequence analysis tools framework in 2024</article-title>. <source>Nucleic Acids Res.</source> <volume>52</volume>, <fpage>W521</fpage>&#x2013;<lpage>W525</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkae241</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Letisse</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sokol</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Portais</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>IsoCor: correcting MS data in isotope labeling experiments</article-title>. <source>Bioinformatics</source> <volume>28</volume> (<issue>9</issue>), <fpage>1294</fpage>&#x2013;<lpage>1296</lpage>. <pub-id pub-id-type="doi">10.1093/BIOINFORMATICS/BTS127</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ng</surname>
<given-names>C.Yu</given-names>
</name>
<name>
<surname>Farasat</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Maranas</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Salis</surname>
<given-names>H. M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Rational design of a synthetic entner-doudoroff pathway for improved and controllable NADPH regeneration</article-title>. <source>Metab. Eng.</source> <volume>29</volume>, <fpage>86</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymben.2015.03.001</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishiyama</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Birktoft</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Beppu</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Alteration of coenzyme specificity of malate dehydrogenase from thermus flavus by site-directed mutagenesis</article-title>. <source>J. Biol. Chem.</source> <volume>268</volume> (<issue>7</issue>), <fpage>4656</fpage>&#x2013;<lpage>4660</lpage>. <pub-id pub-id-type="doi">10.1016/s0021-9258(18)53446-3</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rathnasingh</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Subramanian</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Catherine</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ashok</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Production of 3-hydroxypropionic acid via malonyl-CoA pathway using recombinant <italic>Escherichia coli</italic> strains</article-title>. <source>J. Biotechnol.</source> <volume>157</volume> (<issue>4</issue>), <fpage>633</fpage>&#x2013;<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbiotec.2011.06.008</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richter</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zienert</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>A single-point mutation enables lactate dehydrogenase from Bacillus subtilis to utilize NAD&#x2b; and NADP&#x2b; as cofactor</article-title>. <source>Eng. Life Sci.</source> <volume>11</volume> (<issue>1</issue>), <fpage>26</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1002/elsc.201000151</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossmann</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Moras</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>K. W.</given-names>
</name>
</person-group> (<year>1974</year>). <article-title>Chemical and biological evolution of a nucleotide-binding protein</article-title>. <source>Nature</source> <volume>250</volume> (<issue>5463</issue>), <fpage>194</fpage>&#x2013;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1038/250194a0</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sauer</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Canonaco</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Heri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Perrenoud</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>The soluble and membrane-bound transhydrogenases UdhA and PntAB have divergent functions in NADPH metabolism of <italic>Escherichia coli</italic>
</article-title>. <source>J. Biol. Chem.</source> <volume>279</volume> (<issue>8</issue>), <fpage>6613</fpage>&#x2013;<lpage>6619</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M311657200</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Activating transhydrogenase and NAD kinase in combination for improving isobutanol production</article-title>. <source>Metab. Eng.</source> <volume>16</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymben.2012.11.008</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shinka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ohse</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ohfu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hirose</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Rapid and sensitive detection of urinary 4-hydroxybutyric acid and its related compounds by gas chromatography&#x2013;mass spectrometry in a patient with succinic semialdehyde dehydrogenase deficiency</article-title>. <source>J. Chromatogr. B</source> <volume>776</volume> (<issue>1</issue>), <fpage>57</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/S1570-0232(02)00126-5</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi-&#xcd;&#xf1;iguez</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Aburto-Rodr&#xed;guez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vilchis-Gonz&#xe1;lez</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Flores</surname>
<given-names>M. E.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Function, kinetic properties, crystallization, and regulation of microbial malate dehydrogenase</article-title>. <source>J. Zhejiang Univ. Sci. B</source> <volume>17</volume> (<issue>4</issue>), <fpage>247</fpage>&#x2013;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1631/jzus.B1500219</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walther</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Calvayrac</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Malbert</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Alkim</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dressaire</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cordier</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2017a</year>). <article-title>Construction of a synthetic metabolic pathway for the production of 2,4-dihydroxybutyric acid from homoserine</article-title>. <source>Metab. Eng.</source> <volume>45</volume>, <fpage>237</fpage>&#x2013;<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymben.2017.12.005</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walther</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dressaire</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cordier</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Francois</surname>
<given-names>J.-M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Method of production of 2,4-dihydroxybutyric acid</article-title>. <source>U. S. 2015/0159182 A1</source>.</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walther</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Topham</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Irague</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Auriol</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Baylac</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cordier</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2017b</year>). <article-title>Construction of a synthetic metabolic pathway for biosynthesis of the non-natural methionine precursor 2,4-dihydroxybutyric acid</article-title>. <source>Nat. Commun.</source> <volume>8</volume> (<issue>1</issue>), <fpage>15828</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms15828</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wellner</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lichtenberg</surname>
<given-names>L. A.</given-names>
</name>
</person-group> (<year>1971</year>). <article-title>[218a] Assay of amino acid oxidase</article-title>. <source>Methods Enzym.</source> <volume>17</volume>, <fpage>593</fpage>&#x2013;<lpage>596</lpage>. <pub-id pub-id-type="doi">10.1016/0076-6879(71)17104-2</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Yu</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>High-level production of L-homoserine using a non-induced, non-auxotrophic <italic>Escherichia coli</italic> chassis through metabolic engineering</article-title>. <source>Bioresour. Technol.</source> <volume>327</volume> (<issue>29</issue>), <fpage>124814</fpage>. <pub-id pub-id-type="doi">10.1016/j.biortech.2021.124814</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ulrich</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Reymond</surname>
<given-names>J. L.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>An efficient one-step site-directed and site-saturation mutagenesis protocol</article-title>. <source>Nucleic Acids Res.</source> <volume>32</volume> (<issue>14</issue>), <fpage>e115</fpage>. <pub-id pub-id-type="doi">10.1093/nar/gnh110</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>